

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/18225 A1


- (51) International Patent Classification⁷: C12N 15/90, A01K 67/027
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US99/30078
- (22) International Filing Date: 16 December 1999 (16.12.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/152,522 3 September 1999 (03.09.1999) US
- (71) Applicant: XENOCORPORATION [US/US]; 860 Atlantic Avenue, Alameda, CA 94501 (US).
- (72) Inventor: ZHANG, Ning; Xenogen Corporation, 860 Atlantic Avenue, Alameda, CA 94501 (US).
- (74) Agent: SHOLTZ, Charles, K.; Xenogen Corporation, 860 Atlantic Avenue, Alameda, CA 94501 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGETING CONSTRUCTS AND TRANSGENIC ANIMALS PRODUCED THEREWITH



WO 01/18225 A1

(57) Abstract: The present invention teaches targeting constructs and methods of use thereof for creating transgenic animals in which at least one single-copy, non-essential gene is replaced with a reporter expression cassette, for example, a luciferase gene operably linked to a promoter heterologous to the single-copy, non-essential gene. Thus, the present invention provides novel methods and vector constructs useful for the generation of transgenic animals. The invention further includes methods of using these animals.

TARGETING CONSTRUCTS AND TRANSGENIC ANIMALS PRODUCED THEREWITH

5

TECHNICAL FIELD

This invention is in the field of molecular biology and medicine. More specifically, it relates to novel vector constructs and methods of use thereof for introducing heterologous polynucleotides into a host cell. Further, the invention relates to vector constructs and methods of use thereof to generate transgenic organisms, 10 particularly transgenic mice.

BACKGROUND

In recent years, mouse geneticists have succeeded in creating transgenic animals by manipulating the genes of developing embryos and introducing foreign genes into 15 these embryos. Once these genes have integrated into the genome of the recipient embryo, the resulting embryos or adult animals can be analyzed to determine the function of the gene.

Traditionally, transgenic mice have been generated through DNA microinjection approach. Such an approach leads to the creation of "founder" mice having at least one 20 copy of the transgene randomly integrated into the genome. Because neither the copy number nor the integration sites can be controlled, transgenic mice generated by this method are genetically different from each other. The expression of transgenes in such transgenic mice are not uniform because of, for example, the difference in copy numbers of the transgene. Furthermore, chromosomal location of the transgene often affects the 25 expression level of the transgene. For most of *in vivo* studies, particularly ones where it is desirable to compare levels of gene expression across different animals, it is important to have the mice with little or no genetic variation (i.e., isogenic mice) in order to reduce the systematic error.

One way of controlling copy number and the chromosomal integration site is by 30 using targeting constructs to create transgenic animals. U.S. Patent Nos. 5,464,764 and 5,487,992 describe this type of transgenic animal in which a gene of interest is deleted or mutated sufficiently to disrupt its function. These "knock-out" animals are made by taking advantage of the phenomena of homologous recombination. (*See, also* U.S.

- Patent Nos. 5,631,153 and 5,627,059). Using the "knock-out" approach, when the vector is introduced into the embryonic stem cell, a sequence becomes integrated into a target gene in the genome via homologous recombination. The integration disrupts the function of the target gene allows for examination of the phenotype resulting from the
- 5 disruption of the gene. Neither of the above methods, however, provide a predictable approach for the generation of gene expression reporter transgenic animals which can be used for quantitative comparisons of gene expression across different animals transfected with the same construct, or for quantitative comparisons of the relative levels of expression of two or more different genes.
- 10 The present invention solves this and other problems by providing transgenic animals in which at least one single-copy, non-essential gene is replaced with a reporter expression cassette, for example, a luciferase gene operably linked to a heterologous promoter. Thus, the present invention provides novel methods and vector constructs useful for the generation of transgenic animals. The invention further includes methods
- 15 of using these animals.

SUMMARY OF THE INVENTION

The transgenic animals described herein are useful, for example, when studying *in vivo* regulation of selected genes. Also described herein are methods of generating

20 populations of substantially isogenic transgenic animals, as well as, vectors useful in these methods.

Accordingly, in one embodiment, the subject invention is directed to a transgenic, non-human mammal, for example, a rodent such as a mouse. The mammal comprises at least one single-copy, non-essential gene in its genome, wherein (i) at least a portion of

25 at least one single-copy, non-essential gene is replaced by polynucleotide sequences heterologous to the gene, and (ii) the polynucleotide sequences comprise a first expression cassette which has been introduced into the mammal or an ancestor of the mammal, at an embryonic stage. The first expression cassette typically comprises a first selectable marker, a first transcriptional promoter element heterologous to the gene, and

30 light-generating protein coding sequences. The light-generating protein coding sequences are operably linked to the promoter element.

The single-copy, non-essential gene may be selected, for example, from the group consisting of vitronectin, *fosB*, and galactin 3 and the first selectable marker may be selected from the group consisting of neomycin phosphotransferase II, xanthine-guanine phosphoribosyltransferase, hygromycin-B-phosphotransferase, chloramphenicol

5 acetyltransferase, and adeninephosphoribosyl transferase.

In alternative embodiments, the first transcriptional promoter element is an inducible promoter, a repressible promoter, or a constitutive promoter, and may be selected from the group consisting of VEGF, VEGFR, and TIE2.

In additional embodiments, the transgenic, non-human mammal described above

10 comprises a second single-copy, non-essential gene in its genome, wherein (i) at least a portion of the second single-copy, non-essential gene is replaced by polynucleotide sequences heterologous to the second gene, and (ii) the polynucleotide sequences comprise a second expression cassette which has been introduced into the mammal or an ancestor of the mammal, at an embryonic stage. The second expression cassette

15 typically comprises a second selectable marker, a second transcriptional promoter element heterologous to the second gene, and light generating protein coding sequences. The light generating protein coding sequences are operably linked to the promoter element.

The first and second transcriptional promoter elements and selectable markers

20 may be the same or different and the light generating protein in the first expression cassette can produce a different color of light relative to the light generating protein in the second expression cassette.

In yet a further embodiment, the invention is directed to a method of producing a transgenic, non-human mammal, such as a mouse. The mammal has at least one single-copy, non-essential gene in its genome. The method comprises

25 transfecing an embryonic stem cell of the mammal with a linear vector comprising

(a) a first selectable marker and a reporter expression cassette, the reporter expression cassette comprising a transcriptional promoter element operably linked to a

30 light generating protein coding sequence, and

(b) targeting polynucleotide sequences homologous to a single-copy, non-essential gene in said mammal's genome, the targeting polynucleotide sequences

flanking (a), wherein (i) the length of the polynucleotide sequences are sufficient to facilitate homologous recombination between the vector and the single-copy, non-essential gene, and (ii) the transcriptional promoter element is heterologous to the single-copy, non-essential gene;

- 5 selecting embryonic stem cells which each have the first selectable marker and reporter expression cassette integrated into its genome;
 - injecting the embryonic stem cells into a host embryo,
 - implanting the embryo in a foster mother,
 - maintaining the foster mother under conditions which allow production of an
- 10 offspring that is a transgenic, non-human mammal carrying the reporter expression cassette.

In certain embodiments, the offspring is capable of germline transmission of the reporter expression cassette and the method may further comprise breeding the offspring with a mammal which is substantially isogenic with the embryonic stem cells, such that

- 15 the breeding yields transgenic F1 offspring carrying the reporter cassette. In particular embodiments, the method comprises breeding the first F1 offspring carrying the reporter cassette with a second F1 offspring carrying the reporter cassette, wherein the breeding yields transgenic F2 offspring carrying the reporter cassette.

In additional embodiments, the embryonic stems cells may be derived from a mouse having a dark coat color, the mammal substantially isogenic with the embryonic stem cells may have a light coat color, and/or the F2 offspring carrying the reporter cassette may have a light coat color. In particular embodiments, the embryonic stems cells are derived from a C57BL/6 mouse having a dark coat color, and the mammal substantially isogenic with the embryonic stem cells is a C57BL/6-Tyr C2j/+ mouse

- 25 having a light coat color.

In still a further embodiment, the subject invention is directed to a vector for use in generating a transgenic non-human mammal, for example, a rodent such as a mouse. The mammal has at least one single-copy, non-essential gene in its genome. The vector comprises

- 30 (a) a first selectable marker and a reporter expression cassette, the reporter expression cassette comprising a transcriptional promoter element operably linked to a light generating protein coding sequence, and

- (b) targeting polynucleotide sequences homologous to a single-copy, non-essential gene in the mammal's genome, the targeting polynucleotide sequences flanking (a), wherein (i) the length of the targeting polynucleotide sequences are sufficient to facilitate homologous recombination between the vector and the single-copy, non-
5 essential gene, and (ii) the transcriptional promoter element is heterologous to the single-copy, non-essential gene.

In certain embodiments, the first selectable marker provides a positive selection and may be selected from the group consisting of neomycin phosphotransferase II, xanthine-guanine phosphoribosyltransferase, hygromycin-B-phosphotransferase,
10 chloramphenicol acetyltransferase, and adeninephosphoribosyl transferase. Additionally, the transcriptional promoter element may be an inducible promoter, a repressible promoter, or a constitutive promoter, and may be selected from the group consisting of VEGF, VEGFR, and TIE2.

In alternative embodiments, the vector further comprises a second selectable
15 marker and at least one target polynucleotide sequence is located between the second selectable marker and the first selectable marker. Additionally, the second selectable marker may provide a negative selection and may be selected from the group consisting of adenosine deaminase, thymidine kinase, and dihydrofolate reductase.

The vectors described above may be circular and may contain at least one
20 restriction site whose cleavage results in a linear vector having the following arrangement of elements: target polynucleotide sequence - (a) - targeting polynucleotide sequences or target polynucleotide sequence - (a) - targeting polynucleotide sequences – (second selectable marker).

The coding sequences of the reporter expression cassette present in the vector
25 may comprise codons that are optimal for expression in a host system into which the expression cassette is to be introduced. Additionally, the targeting polynucleotide sequences from single-copy, non-essential genes may be selected from the group consisting of vitronectin, *fosB*, and galactin 3.

The light-generating protein in the mammals and methods described above may
30 be derived from either procaryotic or eucaryotic sources and, in particularly preferred embodiments, the light generating protein is a luciferase.

These and other embodiments of the present invention will be apparent to those of skill in the art in view of the teachings herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic depicting construction of the pTK53 vector. Polynucleotides encoding PGK-P, Neo and TK and 5' and 3' linkers are introduced into 5 a pKS backbone to produce the vector designated pTK53.

Figure 2 is schematic depicting construction of the pTK-LucR and pTK-LucYG vectors. For pTK-LucR, a polynucleotide encoding LucR is introduced into pTK53. Thus, the pTK-LucR construct contains the PGK-P gene, a neomycin (Neo^r) gene, a thymidine kinase (TK) gene and sequence encoding red luciferase (Luc-R). For pTK-10 LucYG, a polynucleotide encoding LucYG is introduced into pTK53. Thus, the pTK-LucYG construct contains the PGK-P gene, a neomycin (Neo^r) gene, a thymidine kinase (TK) gene and a sequence encoding yellow-green luciferase (Luc-YG).

Figures 3A is a schematic depicting the vector pTKLR-Vn. Sequences homologous to the vitronectin gene are inserted into pTK-LucR such that they flank the 15 Neo^r gene and the Luc-R coding sequence. Figure 3B is a schematic depicting targeting of the linearized pTKLR-Vn vector to the vitronectin chromosomal locus. The VEGF promoter is cloned into the polylinkers between Neo and Luc-R. Upon homologous recombination, the Neo-VEGF-LucR transgene is inserted into the Vn gene. In the figure, (A) shows the targeting vector pTKLR-Vn and (B) shows the mouse vitronectin 20 gene. In the figure, Neo – neomycin resistance encoding sequences; TK – thymidine kinase encoding sequences; LucR – red luciferase from pGL3Red (Dr. Christopher Contag, Stanford University, Stanford, CA). Regions bearing Vn gene translational start and stop codons are indicated with arrows. Poly(A) sequences are placed upstream of the polylinker to prevent or minimize read-through translation. Figure 3C shows the 25 nucleotide sequence of vitronectin (SEQ ID NO:38).

Figure 4A is a schematic depicting the vector pTKLG-Fos. Sequences homologous to the FosB gene are inserted into pTK-LucYG such that they flank the Neo^r gene and the Luc-YG coding sequence. Figure 4B shows the nucleotide sequence of FosB (SEQ ID NO:39).

30 Figure 5A is a schematic depicting targeting of the linearized pTKLG-Fos vector to the FosB chromosomal locus. The VEGFR2 promoter is cloned into the polylinkers between Neo and Luc-YG. Upon homologous recombination, the Neo-VEGFR2-LucYG

transgene will be inserted into a sequence associated with production of FosB. In the figure, (A) shows the targeting vector, and (B) shows the mouse target gene. In the figure, Neo – neomycin resistance encoding sequences; TK – thymidine kinase encoding sequences; LucYG – yellow green luciferase from pGL3-control vector (Promega, Madison, WI). Regions bearing FosB gene translational start and stop codons are indicated with arrows. Poly(A) sequences are placed upstream of the polylinker to prevent or minimize read-through translation. Figure 5B is a schematic depicting targeting of the linearized pTKLG-Fos vector to the FosB chromosomal locus. The TIE2 promoter is cloned into the polylinkers between Neo and Luc-R. Upon homologous recombination, the Neo-Tie2-LucYG transgene is inserted into the FosB gene. In the figure, (A) shows the targeting vector, and (B) shows the mouse target gene. In the figure, Neo – neomycin resistance encoding sequences; TK – thymidine kinase encoding sequences; LucYG – yellow green luciferase from pGL3-control vector (Promega). Regions bearing FosB gene translational start and stop codons are indicated with arrows. Poly(A) sequences are placed upstream of the polylinker to prevent or minimize read-through translation.

Figure 6 depicts PCR conditions for genomic screening for promoters useful in exemplary targeting constructs of the present invention.

Figure 7 depicts generation of targeted transgenic mice using the targeting vectors described herein.

Figure 8 depicts schematic representation of Southern blot analysis of homologous DNA recombination between pTKLG-Fos targeting vector and the FosB gene.

Figure 9 depicts generation of targeted transgenic mice, using the targeting vectors described herein, and crosses using such transgenics as well as their offspring (F1, first generation; F2, second generation).

Figure 10 depicts crosses using transgenic mice of the present invention to generate dual luciferase transgenic mice.

MODES FOR CARRYING OUT THE INVENTION

Throughout this application, various publications, patents, and published patent applications are referred to by an identifying citation. The disclosures of these publications, patents, and published patent specifications referenced in this application 5 are included to more fully describe the state of the art to which this invention pertains.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology and recombinant DNA, which are within the skill of the art. *See, e.g., Sambrook, Fritsch, and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition 10 (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, (F.M. Ausubel et al. eds., 1987); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); PCR 2: A PRACTICAL APPROACH (M.J. McPherson, B.D. Hames and G.R. Taylor eds., 1995) and ANIMAL CELL CULTURE (R.I. Freshney. Ed., 1987).*

As used in this specification and the appended claims, the singular forms "a," 15 "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a mixture of two or more such agents.

Definitions

20 As used herein, certain terms will have specific meanings.

The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably to and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. 25 Non-limiting examples of polynucleotides include a gene, a gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.

A polynucleotide is typically composed of a specific sequence of four nucleotide 30 bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) for thymine (T) when the polynucleotide is RNA). Thus, the term polynucleotide sequence is the alphabetical representation of a polynucleotide molecule. This alphabetical

representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching.

- A "coding sequence" or a sequence which "encodes" a selected polypeptide, is a
- 5 nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide, for example, *in vivo* when placed under the control of appropriate regulatory sequences (or "control elements"). The boundaries of the coding sequence are typically determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but
- 10 is not limited to, cDNA from viral, procaryotic or eucaryotic mRNA, genomic DNA sequences from viral or procaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence. Other "control elements" may also be associated with a coding sequence. A DNA sequence encoding a polypeptide can be optimized for expression in a selected cell by using the
- 15 codons preferred by the selected cell to represent the DNA copy of the desired polypeptide coding sequence. "Encoded by" refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 to 5 amino acids, more preferably at least 8 to 10 amino acids, and even more preferably at least 15 to 20 amino acids from a
- 20 polypeptide encoded by the nucleic acid sequence. Also encompassed are polypeptide sequences which are immunologically identifiable with a polypeptide encoded by the sequence.

- Typical "control elements", include, but are not limited to, transcription promoters, transcription enhancer elements, transcription termination signals,
- 25 polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5' to the coding sequence), translation enhancing sequences, and translation termination sequences. Transcription promoters can include inducible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), and constitutive promoters.

"Expression enhancing sequences" typically refer to control elements that improve transcription or translation of a polynucleotide relative to the expression level in the absence of such control elements (for example, promoters, promoter enhancers, enhancer elements, and translational enhancers (e.g., Shine and Delagarno sequences)).

- 5 "Purified polynucleotide" refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about 90%, of the protein with which the polynucleotide is naturally associated. Techniques for purifying polynucleotides of interest are well-known in the art and include, for example, disruption of the cell
- 10 containing the polynucleotide with a chaotropic agent and separation of the polynucleotide(s) and proteins by ion-exchange chromatography, affinity chromatography and sedimentation according to density.

A "heterologous sequence" as used herein is typically refers to either (i) a nucleic acid sequence that is not normally found in the cell or organism of interest, or (ii) a nucleic acid sequence introduced at a genomic site wherein the nucleic acid sequence does not normally occur in nature at that site. For example, a DNA sequence encoding a polypeptide can be obtained from yeast and introduced into a bacterial cell. In this case the yeast DNA sequence is "heterologous" to the native DNA of the bacterial cell. Alternatively, a promoter sequence from a Tie2 gene can be introduced into the genomic

15 location of a *fosB* gene. In this case the Tie2 promoter sequence is "heterologous" to the native *fosB* genomic sequence.

A "polypeptide" is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or other peptidomimetics. The subunits may be linked by peptide bonds or by other bonds, for example ester, ether, etc. As used herein, the term "amino acid" refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is typically called a polypeptide or a protein.

30 "Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given promoter that is operably linked to a coding sequence (e.g., a reporter expression

cassette) is capable of effecting the expression of the coding sequence when the proper enzymes are present. The promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening untranslated yet transcribed sequences can be present between the 5 promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

"Recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of the polynucleotide 10 with which it is associated in nature; and/or (2) is linked to a polynucleotide other than that to which it is linked in nature. The term "recombinant" as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. "Recombinant host cells," "host cells," "cells," "cell lines," "cell cultures," and other such terms denoting procaryotic microorganisms or eucaryotic cell 15 lines cultured as unicellular entities, are used interchangeably, and refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement to the original parent, due to 20 accidental or deliberate mutation. Progeny of the parental cell which are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence encoding a desired peptide, are included in the progeny intended by this definition, and are covered by the above terms. An "isolated polynucleotide" 25 molecule is a nucleic acid molecule separate and discrete from the whole organism with which the molecule is found in nature; or a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences (as defined below) in association therewith.

Techniques for determining nucleic acid and amino acid "sequence identity" also are known in the art. Typically, such techniques include determining the nucleotide 30 sequence of the mRNA for a gene and/or determining the amino acid sequence encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence. In general, "identity" refers to an exact nucleotide-to-nucleotide or amino acid-to-amino

acid correspondence of two polynucleotides or polypeptide sequences, respectively.

Two or more sequences (polynucleotide or amino acid) can be compared by determining their "percent identity." The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequences and multiplied by 100. An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M.O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, Nucl. Acids Res. 14(6):6745-6763 (1986). An exemplary implementation of this algorithm to determine percent identity of a sequence is provided by the Genetics Computer Group (Madison, WI) in the "BestFit" utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, WI). A preferred method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used using the following default parameters: genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs can be found at the following internet address: <http://www.ncbi.nlm.gov/cgi-bin/BLAST>. When claiming sequences relative to sequences of the present invention, the desired degrees of sequence identity are at least

80%, 85-90%, preferably 92%, more preferably 95%, and even more preferably 98% sequence identity to the reference sequence (i.e., the sequences of the present invention).

- Alternatively, the degree of sequence similarity between polynucleotides can be determined by hybridization of polynucleotides under conditions that form stable
- 5 duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 80%-85%, preferably at least about 85%-90%, more preferably at least about 90%-95%, and most preferably at least about 95%-98%
 - 10 sequence identity over a defined length of the molecules, as determined using the methods above. As used herein, substantially homologous also refers to sequences showing complete identity to the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that
 - 15 particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., *supra*; *DNA Cloning, supra*; *Nucleic Acid Hybridization, supra*.

- Two nucleic acid fragments are considered to "selectively hybridize" as described herein. The degree of sequence identity between two nucleic acid molecules affects the
- 20 efficiency and strength of hybridization events between such molecules. A partially identical nucleic acid sequence will at least partially inhibit a completely identical sequence from hybridizing to a target molecule. Inhibition of hybridization of the completely identical sequence can be assessed using hybridization assays that are well known in the art (e.g., Southern blot, Northern blot, solution hybridization, or the like,
 - 25 see Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, (1989) Cold Spring Harbor, N.Y.). Such assays can be conducted using varying degrees of selectivity, for example, using conditions varying from low to high stringency. If conditions of low stringency are employed, the absence of non-specific binding can be assessed using a secondary probe that lacks even a partial degree of sequence identity
 - 30 (for example, a probe having less than about 30% sequence identity with the target molecule), such that, in the absence of non-specific binding events, the secondary probe will not hybridize to the target.

- When utilizing a hybridization-based detection system, a nucleic acid probe is chosen that is complementary to a target nucleic acid sequence, and then by selection of appropriate conditions the probe and the target sequence "selectively hybridize," or bind, to each other to form a hybrid molecule. A nucleic acid molecule that is capable of
- 5 hybridizing selectively to a target sequence under "moderately stringent" typically hybridizes under conditions that allow detection of a target nucleic acid sequence of at least about 10-14 nucleotides in length having at least approximately 70% sequence identity with the sequence of the selected nucleic acid probe. Stringent hybridization conditions typically allow detection of target nucleic acid sequences of at least about 10-
- 10 14 nucleotides in length having a sequence identity of greater than about 90-95% with the sequence of the selected nucleic acid probe. Hybridization conditions useful for probe/target hybridization where the probe and target have a specific degree of sequence identity, can be determined as is known in the art (see, for example, Nucleic Acid Hybridization: A Practical Approach, editors B.D. Hames and S.J. Higgins, (1985)
- 15 Oxford; Washington, DC; IRL Press).

With respect to stringency conditions for hybridization, it is well known in the art that numerous equivalent conditions can be employed to establish a particular stringency by varying, for example, the following factors: the length and nature of probe and target sequences, base composition of the various sequences, concentrations of salts and other

20 hybridization solution components, the presence or absence of blocking agents in the hybridization solutions (e.g., formamide, dextran sulfate, and polyethylene glycol), hybridization reaction temperature and time parameters, as well as, varying wash conditions. The selection of a particular set of hybridization conditions is selected following standard methods in the art (see, for example, Sambrook, et al., Molecular

25 Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.).

A "vector" is capable of transferring gene sequences to target cells. Typically, "vector construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression

30 vehicles, as well as integrating vectors.

"Nucleic acid expression vector" or "expression cassette" refers to an assembly which is capable of directing the expression of a sequence or gene of interest. The

nucleic acid expression vector includes a promoter which is operably linked to the sequences or gene(s) of interest. Other control elements may be present as well. Expression cassettes described herein may be contained within a plasmid construct. In addition to the components of the expression cassette, the plasmid construct may also 5 include a bacterial origin of replication, one or more selectable markers, a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a M13 origin of replication), a multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).

An "expression cassette" comprises any nucleic acid construct capable of 10 directing the expression of a gene/coding sequence of interest. Such cassettes can be constructed into a "vector," "vector construct," "expression vector," or "gene transfer vector," in order to transfer the expression cassette into target cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.

"Luciferase," unless stated otherwise, includes prokaryotic and eukaryotic 15 luciferases, as well as variants possessing varied or altered optical properties, such as luciferases that produce different colors of light (e.g., Kajiyama, N., and Nakano, E., *Protein Engineering* 4(6):691-693 (1991)).

"Light-generating" is defined as capable of generating light through a chemical reaction or through the absorption of radiation.

20 A "light generating protein" or "light-emitting protein" is a protein capable of generating light in the visible spectrum (between approximately 350 nm and 800 nm). Examples include bioluminescent proteins such as luciferases, e.g., bacterial and firefly luciferases, as well as fluorescent proteins such as green fluorescent protein (GFP).

"Light" is defined herein, unless stated otherwise, as electromagnetic radiation 25 having a wavelength of between about 300 nm and about 1100 nm.

"Animal" as used herein typically refers to a non-human mammal, including, without limitation, farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, 30 turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.

A "transgenic animal" refers to a genetically engineered animal or offspring of genetically engineered animals. A transgenic animal usually contains material from at least one unrelated organism, such as from a virus, plant, or other animal. The "non-human animals" of the invention include vertebrates such as rodents, non-human primates, sheep, dogs, cows, amphibians, birds, fish, insects, reptiles, etc. The term "chimeric animal" is used to refer to animals in which the heterologous gene is found, or in which the heterologous gene is expressed in some but not all cells of the animal.

"Analyte" as used herein refers to any compound or substance whose effects (e.g., induction or repression of a specific promoter) can be evaluated using the test animals and methods of the present invention. Such analytes include, but are not limited to, chemical compounds, pharmaceutical compounds, polypeptides, peptides, polynucleotides, and polynucleotide analogs. Many organizations (e.g., the National Institutes of Health, pharmaceutical and chemical corporations) have large libraries of chemical or biological compounds from natural or synthetic processes, or fermentation broths or extracts. Such compounds/analytes can be employed in the practice of the present invention.

As used herein, the term "positive selection marker" refers to a gene encoding a product that enables only the cells that carry the gene to survive and/or grow under certain conditions. For example, plant and animal cells that express the introduced neomycin resistance (Neo^r) gene are resistant to the compound G418. Cells that do not carry the Neo^r gene marker are killed by G418. Other positive selection markers will be known to those of skill in the art. Typically, positive selection markers encode products that can be readily assayed. Thus, positive selection markers can be used to determine whether a particular DNA construct has been introduced into a cell, organ or tissue.

"Negative selection marker" refers to gene encoding a product which can be used to selectively kill and/or inhibit growth of cells under certain conditions. Non-limiting examples of negative selection inserts include a herpes simplex virus (HSV)-thymidine kinase (TK) gene. Cells containing an active HSV-TK gene are incapable of growing in the presence of gancyclovir or similar agents. Thus, depending on the substrate, some gene products can act as either positive or negative selection markers.

The term "homologous recombination" refers to the exchange of DNA fragments between two DNA molecules or chromatids at the site of essentially identical nucleotide

sequences. It is understood that substantially homologous sequences can accommodate insertions, deletions, and substitutions in the nucleotide sequence. Thus, linear sequences of nucleotides can be essentially identical even if some of the nucleotide residues do not precisely correspond or align (see, above).

5 A "knock-out" mutation refers to partial or complete loss of expression of at least a portion the target gene. Examples of knock-out mutations include, but are not limited to, gene-replacement by heterologous sequences, gene disruption by heterologous sequences, and deletion of essential elements of the gene (e.g., promoter region, portions of a coding sequence). A "knock-out" mutation is typically identified by the phenotype
10 generated by the mutation.

A "single-copy gene" as used herein refers to a gene represented in an organism's genome only by a single copy at a particular chromosomal locus. Accordingly, a diploid organism has two copies of the gene and both copies occur at the same chromosomal location.

15 A "gene" as used in the context of the present invention is a sequence of nucleotides in a genetic nucleic acid (chromosome, plasmid, etc.) with which a genetic function is associated. A gene is a hereditary unit, for example of an organism, comprising a polynucleotide sequence (e.g., a DNA sequence for mammals) that occupies a specific physical location (a "gene locus" or "genetic locus") within the
20 genome of an organism. A gene can encode an expressed product, such as a polypeptide or a polynucleotide (e.g., tRNA). Alternatively, a gene may define a genomic location for a particular event/function, such as the binding of proteins and/or nucleic acids (e.g., phage attachment sites), wherein the gene does not encode an expressed product.
Typically, a gene includes coding sequences, such as, polypeptide encoding sequences,
25 and non-coding sequences, such as, promoter sequences, poly-adenylation sequences, transcriptional regulatory sequences (e.g., enhancer sequences). Many eucaryotic genes have "exons" (coding sequences) interrupted by "introns" (non-coding sequences). In certain cases, a gene may share sequences with another gene(s) (e.g., overlapping genes).

30 "Isogenic" means two or more organisms or cells that are considered to be genetically identical. "Substantially isogenic" means two or more organisms or cells wherein, at the majority of genetic loci (e.g., greater than 99.000%, preferably more than 99.900%, more preferably greater than 99.990%, even more preferably greater than

- 99.999%), there exists genetic identity between the organisms or cells being compared.
- In the context of the present invention, two organisms (for example, mice) are considered to be "substantially isogenic" if, for example, inserted transgenes are the primary differences between the genetic make-up of the mice being compared. Further, if, for
- 5 example, the genetic backgrounds of the mice being compared are the same with the exception that one of the mice has one or several defined mutation(s) (for example, affecting coat color), then these mice are considered to be substantially isogenic. An example of two strains of substantially isogenic mice are C57BL/6 and C57BL/6-Tyr C2j/+.
- 10 A "pseudogene" as used herein, refers to a type of gene sequence found in the genomes, typically, of eucaryotes, where the sequence closely resembles a known functional gene, but differs in that the pseudogene is non-functional. For example, the pseudogene sequence may contain several stop codons in what would correspond to an open reading frame in the functional gene. Pseudogenes can also have deletions or
- 15 insertions relative to their corresponding functional gene. If, for example, in a genome there is a functional gene and a related pseudogene, the functional gene is considered to be a single-copy gene (accordingly, the pseudogene is considered to be single-copy as well).
- A "non-essential gene" refers to a gene whose deletion, disruption, elimination,
- 20 reduction of gene function, or mutation is non-lethal, and does not obviously adversely affect the organisms' ability to mature and reproduce. A "non-essential gene with no phenotype" refers to a non-essential gene whose deletion, disruption, elimination, reduction of gene function or mutation has no deleterious effect on the organism.
- Typically there are no phenotypically reflected gene dosage effects associated with
- 25 modification of a non-essential gene with no phenotype -- for example, deletion, disruption or mutation of both copies of a non-essential gene with no phenotype in a diploid organism has essentially the same effect as deletion, disruption, or mutation of one of the two copies present in the diploid organism. In the context of the present invention, a non-essential gene is typically one whose function has been eliminated (e.g.,
- 30 by a deletion mutation) and such elimination of function was non-lethal and the organism developed, matured, and was able to reproduce.

The "native sequence" or "wild-type sequence" of a gene is the polynucleotide sequence that comprises the genetic locus corresponding to the gene, e.g., all regulatory and open-reading frame coding sequences required for expression of a completely functional gene product as they are present in the wild-type genome of an organism. The native sequence of a gene can include, for example, transcriptional promoter sequences, translation enhancing sequences, introns, exons, and poly-A processing signal sites. It is noted that in the general population, wild-type genes may include multiple prevalent versions that contain alterations in sequence relative to each other and yet do not cause a discernible pathological effect. These variations are designated "polymorphisms" or "allelic variations."

By "replacement sequence" is meant a polynucleotide sequence that is substituted for at least a portion of the native or wild-type sequence of a gene.

"Linear vector" or "linearized vector," as used herein, is a vector having two ends. For example, circular vectors, such as plasmids, can be linearized by digestion with a restriction endonuclease that cuts at a single site in the plasmid. Preferably, the targeting vectors described herein are linearized such that the ends are not within the targeting sequences.

General Overview

The present invention relates to vector constructs and methods of creating transgenic animals to be used, for example, as test systems. Methods of using the animals of the present invention include, but are not limited to, using these animals for studies involving tumor growth and other disease conditions. In the practice of the present invention, transgenic, non-human mammals are constructed where a single-copy, non-essential gene is replaced by a reporter expression cassette, preferably a gene encoding a light-generating protein, such as a luciferase-encoding gene, operably linked to a promoter. A variety of promoters are useful in the practice of the present invention, for example, promoters derived from genes associated with tumorigenesis or angiogenesis. Thus, an exemplary promoter can be one that is associated with proteins induced during tumorigenesis, for instance in the presence of tumor generating compounds or of tumors themselves. In this way, expression of the reporter cassette is induced in the animal when, for example, tumors are present, and progression of the

tumor can be evaluated by non-invasive imaging methods using the whole animal.

Another exemplary promoter is one that is derived from a gene associated with angiogenesis. Because the promoter is linked to a reporter such as luciferase, non-invasive monitoring of the progression of angiogenesis is possible.

- 5 Various forms of the different embodiments of the invention, described herein, may be combined.

Non-invasive imaging and/or detecting of light-emitting conjugates in mammalian subjects was described in U.S. Patent No. 5,650,135, by Contag, et al., issued 22 July 1997. This imaging technology can be used in the practice of the present

- 10 invention in view of the teachings of the present specification. In the imaging method, the conjugates contain a biocompatible entity and a light-generating moiety.

Biocompatible entities include, but are not limited to, small molecules such as cyclic organic molecules; macromolecules such as proteins; microorganisms such as viruses, bacteria, yeast and fungi; eukaryotic cells; all types of pathogens and pathogenic

- 15 substances; and particles such as beads and liposomes. In another aspect, biocompatible entities may be all or some of the cells that constitute the mammalian subject being imaged, for example, cells carrying the vector constructs of the present invention expressing a reporter expression cassette.

Light-emitting capability is conferred on the biocompatible entities by the 20 conjugation of a light-generating moiety. Such moieties include fluorescent molecules, fluorescent proteins, enzymatic reactions giving off photons and luminescent substances, such as bioluminescent proteins. In the context of the present invention, light emitting capability is typically conferred on target cells by having at least one copy of a light-generating protein, *e.g.*, a luciferase, present. In preferred embodiments, luciferase is 25 operably linked to appropriate control elements which can facilitate expression of a polypeptide having luciferase activity. Substrates of luciferase can be endogenous to the cell or applied to the cell or system (*e.g.*, injection into a transgenic mouse, having cells carrying a luciferase construct, of a suitable substrate for the luciferase, for example, luciferin). The conjugation may involve a chemical coupling step, genetic engineering of 30 a fusion protein, or the transformation of a cell, microorganism or animal to express a light-generating protein.

Targeting Constructs

The targeting cassettes described herein typically include the following components: (1) a suitable vector backbone; (2) a polynucleotide encoding a light generating protein (3) a promoter operably linked to the light generating protein-
5 encoding gene, wherein the promoter is heterologous to the light generating protein coding sequences; (4) a sequence encoding a positive selection marker; (5) insertion sites flanking the sequence encoding the positive selection marker and the polynucleotide encoding a light generating protein gene, for insertion of sequences which target a single-copy, non-essential chromosomal gene; and, optionally, (6) a sequence encoding a
10 negative selection marker. Exemplary targeting constructs are shown in Figures 3B, 5A and 5B and described in Examples 1-3.

Suitable vector backbones generally include an F1 origin of replication; a colE1 plasmid-derived origin of replication; polyadenylation sequence(s); sequences encoding antibiotic resistance (*e.g.*, ampicillin resistance) and other regulatory or control elements.
15 Non-limiting examples of appropriate backbones include: pBluescriptSK (Stratagene, La Jolla, CA); pBluescriptKS (Stratagene, La Jolla, CA) and other commercially available vectors.

In one aspect of the invention the light generating protein is luciferase. Luciferase coding sequences useful in the practice of the present invention include, but
20 are not limited to, sequences obtained from *lux* genes (procaryotic genes encoding a luciferase activity) and *luc* genes (eucaryotic genes encoding a luciferase activity). A variety of luciferase encoding genes have been identified including, but not limited to, the following: B.A. Sherf and K.V. Wood, U.S. Patent No. 5,670,356, issued 23 September 1997; Kazarni, J., et al., U.S. Patent No. 5,604,123, issued 18 February 1997;
25 S. Zenno, et al, U.S. Patent No. 5,618,722; K.V. Wood, U.S. Patent No. 5,650,289, issued 22 July 1997; K.V. Wood, U.S. Patent No. 5,641,641, issued 24 June 1997; N. Kajiyama and E. Nakano, U.S. Patent No. 5,229,285, issued 20 July 1993; M.J. Cormier and W.W. Lorenz, U.S. Patent No. 5,292,658, issued 8 March 1994; M.J. Cormier and W.W. Lorenz, U.S. Patent No. 5,418,155, issued 23 May 1995; de Wet, J.R., et al,
30 *Molec. Cell. Biol.* 7:725-737, 1987; Tatsumi, H.N., et al, *Biochim. Biophys. Acta* 1131:161-165, 1992; and Wood, K.V., et al, *Science* 244:700-702, 1989. Eukaryotic luciferase catalyzes a reaction using luciferin as a luminescent substrate to produce light,

whereas prokaryotic luciferase catalyzes a reaction using an aldehyde as a luminescent substrate to produce light.

- Wild-type firefly luciferases typically have an emission maxima at about 550 nm. Numerous variants with differing emission maxima have also been studied. For example, Kajiyama and Nakano (*Protein Eng.* 4(6):691-693, 1991; U.S. Patent No. 5,330,906, issued 19 July 1994) teach five variant firefly luciferases generated by single amino acid changes to the *Luciola cruciata* luciferase coding sequence. The variants have emission peaks of 558 nm, 595 nm, 607 nm, 609 nm and 612 nm. A yellow-green luciferase with an emission peak of about 540 nm is commercially available from Promega, Madison, WI under the name pGL3. A red luciferase with an emission peak of about 610 nm is described, for example, in Contag et al. (1998) *Nat. Med.* 4:245-247 and Kajiyama et al. (1991) *Prot. Eng.* 4:691-693.

- Positive selection markers include any gene which a product that can be readily assayed. Examples include, but are not limited to, a hprt gene (Littlefield, J. W., *Science* 145:709-710 (1964)), a xanthine-guanine phosphoribosyltransferase (gpt) gene, or an adenosine phosphoribosyltransferase (aprt) gene (Sambrook et al., *supra*), a thymidine kinase gene (i.e "TK") and especially the TK gene of herpes simplex virus (Giphart-Gassler, M. et al., *Mutat. Res.* 214:223-232 (1989)), a nptII gene (Thomas, K. R. et al., *Cell* 51:503-512 (1987); Mansour, S. L. et al., *Nature* 336:348-352 (1988)), or other genes which confer resistance to amino acid or nucleoside analogues, or antibiotics, etc, for example, gene sequences which encode enzymes such as dihydrofolate reductase (DHFR) enzyme, adenosine deaminase (ADA), asparagine synthetase (AS), hygromycin B phosphotransferase, or a CAD enzyme (carbamyl phosphate synthetase, aspartate transcarbamylase, and dihydroorotate). Addition of the appropriate substrate of the positive selection marker can be used to determine if the product of the positive selection marker is expressed, for example cells which do not express the positive selection marker nptII, are killed when exposed to the substrate G418 (Gibco BRL Life Technology, Gaithersburg, MD).

- The targeting vector typically contains insertion sites for inserting targeting sequences (e.g., sequences that are substantially homologous to the target sequences in the host genome where integration of the targeting vector/expression cassette is desired). These insertion sites are preferably included such that there are two sites, one site on

either side of the sequences encoding the positive selection marker, light generating protein (e.g., luciferase) and the promoter. Insertion sites are, for example, restriction endonuclease recognition sites, and can, for example, represent unique restriction sites. In this way, the vector can be digested with the appropriate enzymes and the targeting sequences ligated into the vector.

Optionally, the targeting construct can contain a polynucleotide encoding a negative selection marker. Suitable negative selection markers include, but are not limited to, HSV-tk (see, e.g., Majzoub et al. (1996) *New Engl. J. Med.* 334:904-907 and U.S. Patent No. 5,464,764), as well as genes encoding various toxins including the diphtheria toxin, the tetanus toxin, the cholera toxin and the pertussis toxin. A further negative selection marker gene is the hypoxanthine-guanine phosphoribosyl transferase (HPRT) gene for negative selection in 6-thioguanine.

Exemplary promoters and single-copy, non-essential genes for use in the vector constructs and methods of the present invention are described below.

15

Promoters

The targeting constructs and transgenic animals described herein contain a sequence encoding a light generating protein, e.g., luciferase, gene operably linked to a promoter. The promoter may be from the same species as the transgenic animal (e.g., mouse promoter used in construct to make transgenic mouse) or from a different species (e.g., human promoter used in construct to make transgenic mouse). The promoter can be derived from any gene of interest. In one embodiment of the present invention, the promoter is derived from a gene whose expression is induced during angiogenesis, for example pathogenic angiogenesis like tumor development. Thus, when a tumor begins to develop in a transgenic animal carrying a vector construct of the present invention, the promoter is induced and the animal expresses luciferase, which can then be monitored *in vivo*.

Exemplary promoters for use in the present invention are selected such that they are functional in a cell type and/or animal into which they are being introduced. Exemplary promoters include, but are not limited to, promoters obtained from the following mouse genes: vascular endothelial growth factor (VEGF) (VEGF promoter described in U.S. Patent No. 5,916,763; Shima et al. (1996) *J. Bio. Chem.* 271:3877-

3883; sequence available on NCBI under accession number U41383); VEGFR2, also known as Flk-1, (VEGFR-2 promoter described, for example, in Rönicke et al. (1996) *Circ. Res.* 79:277-285; Patterson et al. (1995) *J. Bio. Chem.* 270:23111-23118; Kappel et al. (1999) *Blood* 93:4282-4292; sequence available as accession number X89777 of 5 NCBI database); Tie2, also known as Tek (Tie2 promoter described, for example, in Fadel et al. (1998) *Biochem. J.* 338:335-343; Schlaeger et al. (1995) *Develop.* 121:1089-1098; Schlager et al. (1997) *PNAS USA* 94:3058-3063). VEGF is a specific mitogen for EC *in vitro* and a potent angiogenic factor *in vivo*. In a tumorigenesis study, it was shown that VEGF was critical for the initial subcutaneous growth of T-47D breast carcinoma 10 cells transplanted into nude mice, whereas other angiogenic factors, such as, bFGF can compensate for the loss of VEGF after the tumors have reached a certain size (Yoshiji, H., et al., 1997 *Cancer Research* 57: 3924-28). VEGF is a major mediator of aberrant EC proliferation and vascular permeability in a variety of human pathologic situation, such as, tumor angiogenesis, diabetic retinopathy and rheumatoid arthritis (Benjamin LE, et 15 al., 1997 *PNAS* 94: 8761-66; Soker, S., et al., 1998 *Cell* 92: 735-745). VEGF is synthesized by tumor cells *in vivo* and accumulates in nearby blood vessels. Because leaky tumor vessels initiate a cascade of events, which include plasma extravasation and which lead ultimately to angiogenesis and tumor stroma formation, VEGF plays a pivotal role in promoting tumor growth (Dvorak, H.F., et al., 1991 *J Exp Med* 174:1275-8). 20 VEGF expression was upregulated by hypoxia (Shweiki, D., et al., 1992 *Nature* 359: 843-5). VEGF is also upregulated by overexpression of v-Src oncogene (Mukhopadhyay, D., et al., 1995 *Cancer Res.* 55: 6161-5), c-SRC (Mukhopadhyay, D., et al., 1995 *Nature* 375: 577-81), and mutant ras oncogene (Plate, K.H., et al., 1992 *Nature* 359: 845-8). The tumor suppressor p53 downregulates VEGF expression (Mukhopadhyay, D., et 25 al., 1995 *Cancer Res.* 55: 6161-5).

A number of cytokines and growth factors, including PGF and TPA (Grugel, S., et al., 1995 *J. Biological Chem.* 270: 25915-9), EGF, TGF- β , IL-1, IL-6 induce VEGF mRNA expression in certain type of cells (Ferrara, N., et al., 1997 *Endocr. Rev.* 18: 4-25). Kaposi's sarcoma-associated herpesvirus (KSHV) encoded a G-protein-coupled 30 receptor, a homolog of IL-8 receptor, can activate JNK/SAPK and p38MAPK and increase VEGF production, thus causing cell transformation and tumorigenicity (Bais, C., et al., *Nature* 1998 391:86-9). VEGF overexpression in skin of transgenic mice

induces angiogenesis, vascularhypermeability and accelerated tumor development (Larcher, F., et al., Oncogene 1998 17:303-11).

- VEGF-B (cDNA sequences available on databases) is a mitogen for EC and may be involved in angiogenesis in muscle and heart (Olofsson, B., et al., 1996 Proc Natl Acad Sci U S A 93:2576-81). Shown *in vitro*, binding of VEGF-B to its receptor VEGFR-1 leads to increased expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor, suggesting a role for VEGF-B in the regulation of extracellular matrix degradation, cell adhesion, and migration (Olofsson, B., et al., 1998 Proc Natl Acad Sci U S A 95:11709-14).
- VEGF-C (see, e.g., U.S. Patent No. 5,916,763 and Shima et al., *supra*) may regulate angiogenesis of lymphatic vasculature, as suggested by the pattern of VEGF-C expression in mouse embryos (Kukk, E., et al., 1996 Development 122: 3829-37). Although VEGF-C is also a ligand for VEGFR-2, the functional significance of this potential interaction is unknown. Overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement, suggesting the major function of VEGF-C is through VEGFR-3 rather than VEGFR-2 (Jeltsch M, et al., 1997 Science 276:1423-5). Shown by the CAM assay, VEGF and VEGF-C are specific angiogenic and lymphangiogenic growth factors, respectively (Oh, S.J., et al., (1997) *Devel. Biol.* 188: 96-109). VEGF-C overexpression in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch M, et al., 1997 Science 276:1423-5).
- VEGF-D (cDNA sequences available on databases) is a mitogen for EC. Given that VEGF-D can also activate VEGFR-3, it is possible that VEGF-D could be involved in the regulation of growth and/or differentiation of lymphatic endothelium (Achen, M.G., et al., 1998 Proc Natl Acad Sci U S A 95: 548-53). VEGF-D is induced by transcription factor c-Fos in mouse (Orlandini, M., 1996 PNAS 93: 11675-80).
- VEGFR-1 signaling pathway may regulate normal endothelial cell-cell or cell matrix interactions during vascular development, as suggested by the knockout study (Fong, G.H., et al., 1995 Nature 376: 65-69). Although VEGFR-1 has a higher affinity to VEGF than VEGFR-2, it does not transduce the mitogenic signals of VEGF in ECs (Soker, S., et al., 1998 Cell 92: 735-745). VEGFR-2 (see, e.g., Rönicke et al., Patterson et al., Kappel et al. (1999), *supra*) appears to be the major transducer of VEGF signals in

EC that result in chemotaxis, mitogenicity and gross morphological changes in target cells (Soker, S., et al., 1998 *Cell* 92: 735-745). VEGFR-3 has an essential role in the development of the embryonic cardiovascular system before the emergence of lymphatic vessels, as shown by the knockout study (Dumont, D.J., et al., 1998 *Science* 282: 946-949). Neuropillin-1 (see, e.g., Soker et al. (1998) *Cell* 92:735-745) is a receptor for VEGF165. It can enhance the binding of VEGF165 to VEGFR-2 and VEGF165 mediated chemotaxis (Soker, S., et al., 1998 *Cell* 92: 735-745). Neuropillin 1 overexpression in transgenic mice resulted in embryonic lethality. The embryos possessed excess capillaries and blood vessels. Dilated vessels and hemorrhage were also observed (Kitsukawa, T., et al., 1995 *Development* 121: 4309-18).

Further promoters of interest include, but are not limited to, the following. Ang2 is expressed only at predominant vascular remodeling sites, such as ovary, placenta, uterus (Maisonpierre, P.C., et al., 1997 *Science* 277: 55-60). In glioblastoma angiogenesis, Ang2 is found to be expressed in endothelial cells of small blood vessel and capillaries while Ang1 is expressed in glioblastoma tumor cells (Stratmann, A., 1998 *Am J Pathol* 153: 1459-66). Ang2 is up-regulated in bovine microvascular endothelial by VEGF, bFGF, cytokines, hypoxia (Mandriota, S.J., 1998 *Circ Res* 83: 852-9). Ang2 transgenic overexpression disrupts angiogenesis, and is embryonic lethal (Maisonpierre, P.C., et al., 1997 *Science* 277: 55-60). Ang1 is widely expressed, less abundant in heart and liver (Maisonpierre, P.C., et al., 1997 *Science* 277: 55-60). Ang1 is expressed in mesenchymal cells and may up-regulate the expression of Tie2 in the endothelial cells (Suri, C., et al., 1996 *Cell* 87: 1171-1180). Ang1 overexpression in the skin of transgenic mice produces larger, more numerous, and more highly branched vessels (Suri, C., et al., 1998 *Science* 282:468-71). Tie2 (see, e.g., Fadel et al.; Schlaeger et al. (1995), and Schlager et al. (1997), *supra*) is endothelial cell specific, up-regulated during wound healing, follicle maturation (Puri, M.C., et al., 1995 *EMBO J* 14: 5884-91) and pathologic angiogenesis (Kaipainen, A., 1994 *Cancer Research* 54: 6571-77), such as, glioblastoma (Stratmann, A., 1998 *Am J Pathol* 153: 1459-66). Tie2 is also expressed in non-proliferating adult endothelium and endothelial cell lines (Dumont, D.J., et al. (1994) *Genes & Develop.* 8:1897-1909). A Tie2 activating mutation causes vascular dysmorphogenesis (Vikkula M, et al., 1996 *Cell* 87: 1181-1190). Tie2 mutant overexpression in transgenic mice is embryonic lethal (Dumont, D.J., et al., *supra*).

Other promoters useful in the practice of the present invention include, by way of example, promoters derived from the sequences encoding the following polypeptide products: PTEN (dual specificity phosphatase); BAI (brain-specific angiogenesis inhibitor); KAI1 (KANGAI 1); catenin beta-1 (cadherin-associated protein, beta); COX2 (PTGS2 cyclooxygenase 2, a.k.a. prostaglandin-endoperoxide synthase 2); MMP2 (72 kDa Type IV-A collagenase); MMP9 (92 kDa type IV-B collagenase); TIMP2 (tissue inhibitor of metalloproteinase 2); and TIMP3 (tissue inhibitor of metalloproteinase 3).

PTEN is a tumor suppressor gene and encodes a protein of 403 amino acids. (Li et al. (1997) *Science* 275:1943-1946; DiCristofano et al. (1998) *Nature Genet.* 19:348-355). Overexpression of PTEN has been shown to inhibit cell migration and it is postulated that this protein may function as a tumor suppressor by negatively regulating cell interactions with the extracellular matrix or by negatively regulating the PI3K/PKB/Akt signaling pathway. (Tamura et al. (1998) *Science* 280:1614-1617; Stambolic et al. (1998) *Cell* 95:29-29). Mutations in PTEN have been detected in cancer cell lines and in the germline of patients having Cowden disease, Lhermitte-Duclos disease and Bannayan-Zonana syndrome (diseases and syndromes which are characterized by hyperplastic/dysplastic changes in the prostate, skin and colon and which are associated with an increased risk of certain cancers, for example, breast cancer, prostate cancer and colon cancer). (Marsh et al. (1998) *Hum. Molec. Genet.* 7:507-515; Marsh et al. (1998) *J. Med. Genet.* 35:881-885; Nelen et al. (1997) *Hum. Molec. Genet.* 6:1383-1387).

BAI1 protein is predicted to be 1,584 amino acids in length and includes an extracellular domain, an intracellular domain and a 7-span transmembrane region similar to that of the secretin receptor. (Nishimori et al. (1997) *Oncogene* 15:245-250). The extracellular region of BAI1 has a single Arg-Gly-Asp (RGD) motif recognized by integrins and also has five sequences corresponding to the thrombospondin type I (accession number 188060) repeats that can inhibit angiogenesis includes by basic fibroblast growth factor (bFGF, accession number 134920). Shiratsuchi et al. (1997) *Cytogenet. Cell Genet.* 79:103-108, cloned 2 other brain-specific angiogenesis inhibiting genes, designated BAI2 (accession number 602683) and BAI 3 (accession number 602684). Thus, it is postulated that members of this gene family may play a role in suppression of glioblastoma.

KAI1 encodes a 267 amino acid protein which is a member of the leukocyte surface glycoprotein family. The protein has 4 hydrophobic transmembrane domains and 1 large extracellular hydrophilic domain with three potential N-glycosylation sites. (Dong et al. (1995) *Science* 268:884-886). Molecular analysis of KAI1 is described, for example, in Dong et al. (1997) *Genomics* 41:25-32. KAI1 is a tumor metastasis suppressor gene that is capable of inhibiting the metastatic process in experimental animals. Expression of KAI1 is downregulated during tumor progression of prostate, breast, lung, bladder and pancreatic cancers in humans, apparently at the transcriptional or posttranscriptional level. Mashimo et al. (1998) *PNAS USA* 95:11307-11311, found that the tumor suppressor gene p53 can directly inactivate the KAI1 gene by interacting with the region 5' to the coding sequence, suggesting a direct relationship between p53 and KAI1.

Catenin beta-1 is an adherens junction (AJ) protein, which are critical for establishing and maintaining epithelial cell layers, for instance during embryogenesis, wound healing and tumor cell metastasis. Molecular analysis, including description of sequence homology to plakoglobin (accession number 173325), homology to the drosophila gene "armadillo" and interactions with Lef1/Tcf DNA binding proteins, is described, for example, in Nollet et al. (1996) *Genomics* 32:413-424; McCrea et al. (1991) *Science* 254:1359-1361 and Korinek et al. (1997) *Science* 275:1784-1787. In addition, studies by Korinek et al., *supra* and Morin et al. (1997) *Science* 275:1787-1790, have indicated that APC (accession number 175100) negatively regulates catenin beta and that regulation of this protein is critical to the tumor suppressive effect of APC. Abnormally high levels of beta-catenin have been detected in certain human melanoma cell lines. (Rubinfeld et al. (1997) *Science* 275:1790-1792. Koch et al. (1999) *Cancer Res.* 59:269-273 report that childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Transgenic mice which express catenin beta under the control of an epidermal promoter undergo de novo hair morphogenesis and eventually these animals develop two types of tumors -- epithelioid cysts and trichofolliculomas. Gat et al. (1998) *Cell* 95:605-614.

COX2 encodes a cyclooxygenase and is a key regulator of prostaglandin synthesis. (Hla et al. (1992) *PNAS USA* 89:7384-7388; Jones et al. (1993) *J. Biol. Chem.* 268:9049-9054). In particular, COX2 is generally considered to be a mediator of

inflammation and overexpression of COX2 in rat epithelial cells results in elevated levels of E-cadherin and Bcl2. (Tsujii & DuBois (1995) *Cell* 83:493-501). In co-cultures of endothelial cells and colon carcinoma cells, cells that overexpress COX2 produce prostaglandins, proangiogenic factors and stimulate both endothelial migration and tube formation. (Tsujii et al. (1998) *Cell* 93:705-716). Experiments conducted using APC knock-out mice have demonstrated that animals homozygous for a disrupted COX2 locus develop significantly more adenomatous polyps. (Oshima et al. (1996) *Cell* 87:803-809). COX-2 "knock out" mice develop severe nephropathy, are susceptible to peritonitis, exhibit reduced arachidonic acid-induced inflammation and exhibit reduced indomethacin-induced gastric ulceration. (Morham et al. (1995) *Cell* 83:473-482; Langenbach et al. (1995) *Cell* 83:483-492). Female mice that are deficient in cyclooxygenase 2 exhibit multiple reproductive failures. (Lim et al. (1997) *Cell* 91:197-208).

MMP2 is a metalloproteinase that specifically cleaves type IV collagen. A C-terminal fragment of MMP2, termed PEX, prevents normal binding to alpha-V/beta-3 and disrupts angiogenesis and tumor growth. (Brooks et al. (1998) *Cell* 92:391-400).

MMP9 is a collagenase secreted from normal skin fibroblasts. MMP9 null mice exhibit an abnormal pattern of skeletal growth plate vascularization and ossification. (Vu et al. (1998) *Cell* 93:411-422).

TIMP2 is a collagenase and appears to play a major role in modulating the activity of interstitial collagenase and a number of connective tissue metalloendoproteases. (Stetler-Stevenson et al. (1989) *J. Biol. Chem.* 264:17372-17378). Unlike TIMP1 and TIMP3, TIMP2 is not upregulated by TPA or TGF-beta. (Hammani et al. (1996) *J. Biol. Chem.* 271:25498-25505).

TIMP3 (Wilde et al. (1994) *DNA Cell Biol.* 13:711-718) is localized in the extracellular matrix in both its glycosylated and unglycosylated forms. Studies of mutant TIMP3 proteins have demonstrated that C-terminal truncations do not bind to the extracellular matrix. (Langton et al. (1998) *J. Biol. Chem.* 273:16778-16781).

As one of skill in the art will appreciate in view of the teachings of the present specification, promoter sequences can be easily derived and isolated from known polypeptide sequences or from cDNA or genomic sequences, using method known in the art in view of the teachings herein. An exemplary method of isolating promoter

sequences using cDNA is via a GenomeWalker® kit, commercially available from Clontech (Palo Alto, CA), and described on page 27 of the 1997-1998 Clontech catalog.

Targeting Sequences: Non-Essential Genes

Central to the present invention is the fact that the targeting constructs contain "targeting" sequences (flanking, for example, the light generating protein-encoding sequence and promoter) derived from a single-copy, non-essential gene. These targeting sequences in the construct act via homologous recombination to replace at least a portion of the non-essential gene in the genome with the light-generating protein-encoding (e.g., luciferase-encoding) sequence operably linked to a promoter.

Non-limiting examples of targeting sequences for use in generating transgenic mice include sequences obtained from or derived from vitronectin, Fos B and galactin 3. A search of Mouse Knockout & Mutation Database (Genome Systems, Inc., St. Louis, MO) can be used to identify genes that have been knocked-out in mice where the generated knockout mice displayed no obvious defects. The chromosomal locus for all these genes can be used to target promoter-(light generating protein, e.g., luciferase) transgenes similar to what is described in Example 2. Single-copy, non-essential mouse genes identified in this manner include, but are not limited to, the following: Moesin (Msn), Doi Y., et al., J Biol Chem 1999, 274:2315-2321; Plasminogen activator inhibitor, type II (Planh2) and Planh1, Dougherty K.M., Proc Natl Acad Sci USA 1999, 96:686-691; Protein tyrosine phosphatase, receptor type, B (Ptprb), Elchebly et al. (1999) Science 283:1544-1548; Presenilin 1 (Psen1), Guo Q, et al. (1999) Proc Natl Acad Sci USA, 96:4125-4130; Protein kinase, mitogen-activated 9 (Prkm9) / SAPK/Erk/kinase 2 (Serk2), Kuan CY et al. (1999) Neuron 4:667-676; CD152 antigen (Cd152) / CD86 antigen (Cd86) / CD80 antigen (Cd80), Mandelbrot DA, et al. (1999) J Exp Med, 189:435-440; Poly (ADP-ribose) polymerase (Adprp), Masutani M, et al. (1999), Proc Natl Acad Sci USA 96:2301-2304; Sodium channel, nonvoltage-gated 1 beta (Scnn1b), Pradervand S, et al. (1999) Proc Natl Acad Sci USA 96:1732-1737; Nuclear receptor coactivator 1 (Ncoa1), Qi C, et al. (1999) Proc Natl Acad Sci USA 96:1585-1590; Decay accelerating factor 1 (Daf1), Sun X, et al. (1999) Proc Natl Acad Sci USA 1999, 96:628-633; Necdin (Ndn), Tsai TF, et al. (1999) Nat Genet 22:15-16; Relaxin (Rln); Zhao L, et al. (1999) Endocrinology 140:445-453; Adenylyl cyclase 8

- (Adcy8), Abdel-Majid RM, et al. (1998) *Nat Genet* 19:289–291; Leukemia inhibitory factor (Lif), Bugga L, et al. (1998) *J Neurobiol* 36:509–524; Lectin, galactose binding, soluble 3 (Lgals3) and Lgals1, Calnot C, et al. (1998) *Dev Dyn* 211:306–313; Urokinase plasminogen activator receptor (Plaur) Carmeliet P, et al. (1998) *J Cell Biol* 140:233–245; Nitric oxide synthase 1, neuronal (Nos1), Chao DS, et al. (1998) *J Neurochem* 71:784–789; Homeo box A7 (Hoxa7), Chen F, et al. (1998) *Mech Dev* 77:49–57; Myosin light chain, phosphorylatable, cardiac ventricles (Mylpc) Chen J, et al. (1998) *J Biol Chem* 273:1252–1256; Homeo box B7 (Hoxb7), Chen F, et al. (1998) *Mech Dev* 77:49–57; Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha 5 and beta (Nfkbia and Nfkbb), Cheng JD, et al. (1998) *J Exp Med* 6:1055–1062; Enolase 1, alpha non-neuron (Eno1), Couldrey C, et al. (1998) *Dev Dyn* 212:284–292; Xeroderma pigmentosum, complementation group A (Xpa), De Vries A, et al. (1998) *Exp Eye Res* 1998, 67:53–59; Von Willebrand factor homolog (Vwf), Denis C, et al. (1998) *Proc Natl Acad Sci USA* 95:9524–9529; Lysosomal acid lipase 1 (Lip1), Du H, et al. (1998) *Hum Mol Genet* 7:1347–1354; UNC-5 homolog (*C. elegans*) 3 (Unc5h3), Eisenman LM, et al. (1998) *J Comp Neurol* 394:106–117; Protein phosphatase 1, regulatory (inhibitor) subunit 1B (Ppp1r1b), Fienberg AA, et al. (1998) *Science* 281:838–842; Myelin-associated glycoprotein (Mag) Fujita N, et al. (1998) *J Neurosci* 18:1970–1978; Paraoxonase 1 (Pon1), Furlong CE, et al. (1998) *Neurotoxicology* 19:645–650; Brain derived neurotrophic factor (Bdnf), Garek RR, et al. (1998) *Laryngoscope* 108:671–678; Neurotrophin 3 (Ntf3), Garek RR, et al. (1998) *Laryngoscope* 108:671–678; Myoglobin (Mb); Garry DJ, et al. (1998) *Nature* 395:905–908; Opioid receptor, mu (Oprm), Gaveriaux-Ruff C, et al. (1998) *Proc Natl Acad Sci USA* 95:6326–6330; Neuropeptide Y (Npy), Hollopeter G, et al. (1998) *Int J Obes Relat Metab Disord* 22:506–512; Procollagen, type I, alpha 1 (Cola1) Hormuzdi SG, et al. (1998) *Mol Cell Biol* 18:3368–3375; Centromere autoantigen B (Cenpb), Hudson DF, et al. (1998) *J Cell Biol* 141:309–319; Oculocerebrorenal syndrome of Lowe (ocrl), Janne PA, et al. (1998) *J Clin Invest* 101:2042–2053; arachidonate 12-lipoxygenase (Alox12) Johnson EN, et al. (1998) *Proc Natl Acad Sci USA* 95:3100–3105; H19 fetal liver mRNA (H19), Jones BK, et al. (1998) *Genes Dev* 12:2200–2207; Hepatocyte nuclear factor 3 gamma (winged helix transcription factor) (Hnf3g), Kaestner KH, et al. (1998) *Mol Cell Biol* 18:4245–4251; Bone morphogenetic protein 2 (Bmp2) / Bone

- morphogenetic protein 7 (Bmp7) and Bmp5, Katagiri T, et al. (1998) *Dev Genet* 22:340–348; Intercellular adhesion molecule (Icam1), Ley K, et al. (1998) *Circ Res* 83:287–294; Glutamyl aminopeptidase (Enpep), Lin Q, et al. *J Immunol* 1998, 160:4681–4687; Prion protein (Prnp), Lipp HP, et al. *Behav Brain Res* 1998, 95:47–54; RAB3A, member RAS oncogene family (Rab3a), Lonart G, et al. *Neuron* 1998, 21:1141–1150; Potassium voltage gated channel, shaker related subfamily, member 4 (Kcna4), London B, et al., *J Physiol (Lond)* 1998, 509:171–182; Apurinic/apyrimidinic endonuclease (Apex), Ludwig DL, et al. *Mutat Res* 1998, 409:17–29; T-cell receptor gamma, variable 5 (Tcrg-V5), Mallick-Wood CA, et al. *Science* 1998, 279:1729–1733; Nuclear, factor, erythroid derived 2, like 2 (Nfe2l2), Martin F, et al. *Blood* 1998, 91:3459–3466; Interleukin 13 (Il13), McKenzie GJ, et al. *Curr Biol* 1998, 8:339–340; Sorbitol dehydrogenase 1 (Sdh1), Ng T, et al. *Diabetes* 1998, 47:961–966; Guanine nucleotide binding protein, alpha 11 (Gna11), Offermanns S, et al. *EMBO J* 1998, 17:4304–4312; Estrogen receptor alpha (Estra), Ogawa S, et al. *Endocrinology* 1998, 139:5070–5081; Integrin beta 2 (Itgb2),
Intracellular adhesion molecule (Icam1) and CD34 antigen, Oliveira-dos-Santos AJ, et al. *Eur J Immunol* 1998, 28:2882–2892; Angiotensin receptor 1b (Agtr1b), Oliverio MI, et al. *Proc Natl Acad Sci USA* 1998, 95:15496–15501; Complement factor B (factor B), Pekna M, et al. *Scand J Immunol* 1998, 47:375–380; Centromere autoantigen B (Cenpb), Perez-Castro AV, et al. *Dev Biol* 1998, 201:135–143; Procollagen, type V, alpha 2 (Col5a2) / Fibrillin 1 (Fbn1), Phelps RG, et al. *Mol Med* 1998, 4:356–360; Plasminogen activator inhibitor, type 1 (Planh1), Pinsky DJ, et al. *J Clin Invest* 1998, 102:919–928, Carmeliet P, et al. *J Clin Invest* 1993, 92:2756–2760; Placentae and embryos oncofetal gene (Pem), Pitman JL, et al. *Dev Biol* 1998, 202:196–214; Postmeiotic segregation increased 1 (*S. cerevisiae*) (Pms1), Prolla TA, et al. *Nat Genet* 1998, 18:276–278; Prion protein, structural locus (Prn-p), Prusiner SB, et al. *Proc Natl Acad Sci USA* 1998, 90:10608–10612, Lledo P-M, et al. *Proc Natl Acad Sci U S A* 1996, 93:2403–2407, Sailer A, et al. *Cell* 1994, 77:967–968, Weissmann C, et al. *Philos Trans R Soc Lond [Biol]* 1994, 343:431–433, Bueler H, et al. *Cell* 1993, 73:1337–1347, Weissmann C, et al. *Intervirology* 1993, 35:164–175; NAD (P)H:quinone oxidoreductase, Radjendirane V, et al. *J Biol Chem* 1998, 273:7382–7389; Alpha tropomyosin (Tpm1), Rethinasamy P, et al. *Circ Res* 1998, 82:116–123; Goosecoid and Goosecoid-like (Gscl), Wakamiya M, et al. *Hum Mol Genet* 1998, 7:1835–1840, Saint-Pore B, et al. *Hum Mol Genet* 1998,

- 7:1841–1849; Schlafin 1 (Slfn1); Schwarz DA, et al. *Immunity* 1998, 9:657–668;
Nuclear factor, erythroid derived 2, ubiquitous (Mafk), Shavit JA, et al. *Genes Dev* 1998,
12:2164–2174; Microphthalmia-associated transcription factor (Mitf), Smith SB, et al.
Exp Eye Res 1998, 66:403–410; Bone morphogenetic protein 6 (Bmp6), Solloway MJ, et
al. *Dev Genet* 1998, 22:321–339; Phosphatidylinositol glycan, class A (Piga), Takahama
Y, et al. *Eur J Immunol* 1998, 28:2159–2166; Paired-related homeobox 2 (Prx2), Berge
D, et al. *Development* 1998, 125:3831–3842; Prostaglandin E receptor EP1 subtype
(Ptgerep1), Ushikubi F, et al. *Nature* 1998, 395:281–284; Immunoglobulin kappa chain
complex (Igk), van der Stoep N, et al. *Immunity* 1998, 8:743–750; Adenine
10 phosphoribosyl transferase (Aprt), Van Sloun PP, et al. *Nucleic Acids Res* 1998,
26:4888–4894; Microtubule associated protein 4 (Mtap4), Voss AK, et al. *Dev Dyn*
1998, 212:258–266; 3-hydroxy-3-methylglutaryl-coenzyme A lyase (Hmgcl), Wang
SP, et al. *Hum Mol Genet* 1998, 7:2057–2062; Fibroblast growth factor receptor 4
(Fgfr4), Weinstein M, et al. *Development* 1998, 125:3615–3623; Hepsin (Hpn), Wu Q,
15 et al. *J Clin Invest* 1998, 101:321–326; Small inducible cytokine A11 (Scyall), Yang T,
et al. *Blood* 1998, 92:3912–3923; Small nuclear ribonucleoprotein N (Snrpn), Yang T, et
al. *Nat Genet* 1998, 19:25–31; DNA fragmentation factor, alpha subunit (Dffa), Zhang J,
et al. *Proc Natl Acad Sci USA* 1998, 95:12480–12485; Early growth response 1 (Egr1),
Zheng D, et al. *Neuroscience* 1998, 83:251–258; Early growth response 1 (Egr1) /
20 Hormone receptor (Hmr), Zheng D, et al. *Neuroscience* 1998, 83:251–258;
Hemochromatosis (Hfe), Zhou XY, et al. *Proc Natl Acad Sci USA* 1998, 95:2492–2497;
Alpha tropomyosin (Tpm1), Blanchard EM, et al. *Circ Res* 1997, 81:1005–1010; tRNA
phosphoserine (Trsp), Bosl MR, et al. *Proc Natl Acad Sci U S A* 1997, 94:5531–5534;
Angiotensin receptor 1b (Agtr1b), Chen X, et al. *Am J Physiol* 1997, 272:F299–F304;
25 Xeroderma pigmentosum, complementation group C (Xpc), Cheo DL, et al. *Mut Res*
1997, 374:1–9; B cell leukemia/lymphoma 6 (Bcl6), Dent AL, et al. *Science* 1997,
276:589–592; Fumarylacetoacetate hydrolase (Fah) / 4-hydroxyphenylpyruvic acid
dioxygenase (Hpd), Endo F, et al. *J Biol Chem* 1997, 272:24426–24432; N-
methylpurine-DNA glycosylase (Mpg), Engelward BP, et al. *Proc Natl Acad Sci USA*
30 1997, 94:13087–13092; Interleukin 1 receptor, type 1 (Il1r1), Giaccum MB, et al. *J
Immunol* 1997, 159:3364–3371; N-methylpurine-DNA glycosylase (Mpg), Hang B, et
al. *Proc Natl Acad Sci USA* 1997, 94:12869–12874; Gamma-aminobutyric acid (GABA-

- A) receptor, subunit alpha 6 (Gabra6), Homanics GE, et al. Mol Pharmacol 1997, 51:588–596; Superoxide dismutase 2, mitochondrial (Sod2), Huang TT, et al. Arch Biochem Biophys 1997, 344:424–432; Interleukin 11 receptor, alpha chain 1 (Il11ra1), Nandurjar HH, et al. Blood 1997, 90:2148–2159; Alkaline phosphatase 5 (Akp5),
- 5 Narisawa S, et al. Dev Dyn 1997, 208:432–446; GATA-binding protein 4 (Gata4), Narita N, et al. Development 1997, 124:3755–3764; Lymphocyte protein tyrosine kinase (Lck) / Fyn protooncogene (Fyn); Page ST, et al. Eur J Immunol 1997, 27:554–562; P glycoprotein 3 (Pgy3), Schinkel AH, et al. Proc Natl Acad Sci U S A 1997, 94:4028–4033; P glycoprotein 1 (Pgy1) / P glycoprotein 3 (Pgy3), Schinkel AH, et al., Proc Natl Acad Sci U S A 1997, 94:4028–4033; Creatine kinase, mitochondrial 1, ubiquitous (Ckmt1), Steeghs K, et al. J Neurosci Methods 1997, 71:29–41; T cell receptor gamma, variable 4 (Tcrg-V4), Sunaga S, et al. J Immunol 1997, 158:4223–4228; Ia-associated invariant chain (p31 form) (Ii), Takaesu NT, et al. J Immunol 1997, 158:187–199; Solute carrier family 18 (vesicular monoamine), member 2 (Slc18a2), Takahashi N, et al. Proc
- 10 Natl Acad Sci USA 1997, 94:9938–9943; Matrix metalloproteinase 7 (Mmp7), Wilson CL, et al. Proc Natl Acad Sci U S A 1997, 94:1402–1407; Formin (Fmn), Wynshaw-Boris A, et al. Mol Med 1997, 3:372–384; Synaptophysin (Syp), Arrandale JM, et al. J Biol Chem 1996, 271:21353–21358; Transformation related protein 53 (Trp53), Boehme SA, et al. J Immunol 1996, 156:4075–4078; Neuronal nitric oxide synthase (Nos1),
- 15 Burnett AL, et al. Mol Medicine 1996, 2:288–296; Eph receptor A2 (Epha2), Chen J, et al. Oncogene 1996, 12:979–988; Urokinase plasminogen activator receptor (Plaur); Dowerchin M, et al. J Clin Invest 1996, 97:870–878; Growth differentiation factor 9 (Gdf9), Dong J, et al. Nature 1996, 383:531–535; Externally regulated phosphatase (Ptpn16), Dorfman K, et al. Oncogene 1996, 13:925–931; Tenascin C (Tnc), Forsberg E,
- 20 et al. Proc Natl Acad Sci U S A 1996, 93:6594–6599; Integrin alpha 1 (Itga1), Gardner H, et al. Dev Biol 1996, 175:301–313; FBJ osteosarcoma oncogene B (Fosb), Gruda MC, et al. Oncogene 1996, 12:2177–2185; Breast cancer 1 (Brca1), Hakem R, et al. Cell 1996, 85:1009–1023; Megakaryocyte-associated tyrosine kinase (Matk), Hamaguchi I, et al. Biochem Biophys Res Commun 1996, 224:172–179; Apolipoprotein B editing
- 25 complex 1 (Apobec1), Hirano K-I, et al. J Biol Chem 1996, 271:9887–9890; Carboxyl ester lipase, Howles PN, et al. J. Biol. Chem. 1996, 271:7196–7202; Nuclear factor, erythroid derived 2, ubiquitous (Nfe2u), Kotkow KJ, Orkin SH. Proc Natl Acad Sci U S

- A 1996, 93:3514–3518; Retinoid X receptor gamma (Rxrg), Krezel W, et al. Proc Natl Acad Sci U S A 1996, 93:9010–9014; Early growth response 1 (Egr1), Lee SL, et al. Mol Cell Biol 1996, 16:4566–4572; Adrenergic receptor, alpha 2b (Adra2b), Link RE, et al. Science 1996, 273:803–805; Angiotensin receptor 1a (Agtr1a), Matsusaka T, et al. J Clin Invest 1996, 98:1867–1877; Interleukin 3 receptor, beta chain 1 (Il3rb2), Nicola NA, et al. Blood 1996, 87:2665–2674; Transformation related protein 53 (Trp53), Ohashi M, et al. Jpn J Cancer Res 1996, 87:696–701; Leukemia-associated gene (Lag), Schubart U K, et al. J Biol Chem 1996, 271:14062–14066; Glutathione peroxidase 1 (Gpx1), Spector A, et al. Exp Eye Res 1996, 62:521–540; Arachidonate 12-lipoxygenase, leukocyte (Alox12l), Sun D, Funk CD. J Biol Chem 1996, 271:24055–24062; Complement component 3 (C3), Sylvestre D, et al. J Exp Med 1996, 184:2385–2392; CD30 antigen (Cd30), Texido G, et al. Eur J Immunol 1996, 26:1966–1969; Fc receptor, IgE, low affinity II, alpha polypeptide (Fcer2a), Immunoglobulin heavy chain 5 (delta-like heavy chain) (Igh-5), Interleukin 4 (IL4) and Terminal-deoxynucleotidyl transferase, Texido G, et al. Eur J Immunol 1996, 26:1966–1969; Apolipoprotein A-II (Apoa2), Weng W, Breslow JL. Proc Natl Acad Sci U S A 1996, 93:14788–14794; Amyloid beta (A4) precursor protein (App), Zheng H, et al. Ann N Y Acad Sci 1996, 777:421–426; cAMP responsive element binding protein 1 (Creb1), Blendy JA, et al. Brain Res 1995, 681:8–14; Bradykinin receptor, beta 2 (Bdkrb2), Borkowski JA, et al. J Biol Chem 1995, 270:13706–13710; Growth factor response protein (Gfrp), Crawford PA, et al. Mol Cell Biol 1995, 15:4331–4336; Ciliary neurotrophic factor (Cntf), de Chiara TM, et al. Cell 1995, 83:313–322; Cyclin dependent kinase inhibitor 1A (P21) (Cdkn1a); Deng C, et al. Cell 1995, 82:675–684; Granzyme A (Gzma), Ebnet K, et al. EMBO J 1995, 14:4230–4239; Very low density lipoprotein receptor (Vldlr), Frykman PK, et al. Proc Natl Acad Sci U S A 1995, 92:8453–8457; Apolipoprotein E (Apoe) / Apolipoprotein A-I (Apoa1), Goodrum JF, et al. J Neurobiol 1995, 64:408–416; Nitric oxide synthase 1, neuronal (Nos1), Ichinose F, et al. Anesthesiology 1995, 83:101–108; Nitric oxide synthase 2, inducible, macrophage (Nos2), Laubach VE, et al. Proc Natl Acad Sci U S A 1995, 92:10688–10692; Peroxisome proliferator activated receptor alpha (Ppara), Lee SS-T, et al. Mol Cell Biol 1995, 15:3012–3022; Growth factor response protein (Gfrp), Lee SL, et al. Science 1995, 269:532–535; H19 fetal liver mRNA (H19) / Insulin-like growth factor 2 (Igf2), Leighton PA, et al. Nature 1995, 375:34–39; Retinoic

- acid receptor beta (RAR-beta), Luo J, et al. *Mech Dev* 1995, 53:61–71; Metallothionein 1 (Mt1) / Metallothionein 2 (Mt2), Philcox JC, et al. *Biochem J* 1995, 308:543–546; Heme oxygenase (decycling) 2 (Hmox2), Poss KD, et al. *Neuron* 1995, 15:867–873; H1-0 histone (H1fv), Sirotnik AM, et al. *Proc Natl Acad Sci U S A* 1995, 92:6434–6438;
- 5 Creatine kinase, mitochondrial 1, ubiquitous (Ckmt1), Steeghs K, et al. *Biochim Biophys Acta* 1995, 1230:130–138; Tenascin C (Tnc), Steindler DA, et al. *J Neurosci* 1995, 15:1971–1983; Ia-associated invariant chain (Ii), Takaesu NT, et al. *Immunity* 1995, 3:385–396; Neuroblastoma ras oncogene (Nras), Umanoff H, et al. *Proc Natl Acad Sci USA* 1995, 92:1709–1713; Receptor-associated protein of the synapse, 43 kDa (Rapsn),
- 10 Willnow TE, et al. *Proc Natl Acad Sci USA* 1995, 92:4537–4541; Vitronectin (Vtn), Zheng X, et al. *Proc Natl Acad Sci U S A* 1995, 92:12426–12430; Preproacrosin (Acr), Baba T, et al. *J Biol Chem* 1994, 269:31845–31849; Vimentin (Vim), Colucci GE, et al. *Cell* 1994, 79:679–694; Tumor necrosis factor receptor superfamily, member 1b (Tnfrsf1b), Erickson SL, et al. *Nature* 1994, 372:560–563; Cellular retinoic acid binding
- 15 protein I (Crabp1), Gorry P, et al. *Proc Natl Acad Sci USA* 1994, 91:9032–9036; cAMP responsive element binding protein 1 (Creb1), Hummler F, et al. *Proc Natl Acad Sci USA* 1994, 91:5647–5651; Pore forming protein (Pfp), Kagi D, et al. *Nature* 1994, 369:31–37; Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation site (Srms), Kohmura N, et al. *Mol Cell Biol* 1994, 14:6915–6925; CD3
- 20 polypeptide zeta (Cd3z) / Solute carrier family 22, member 1 (Slc22a1), Koyasu S, et al. *EMBO J* 1994, 13:784–797; Pore forming protein (Pfp), Lowin B, et al. *Proc Natl Acad Sci USA* 1994, 91:11571–11575; Retinoic acid receptor, beta (Rarb), Retinoic acid receptor beta2 (RARbeta2), Mendelsohn C, et al. *Dev Biol* 1994, 166:246–258; Transthyretin (Ttr), Palha JA, et al. *J Biol Chem* 1994, 269:33135–33139; Procollagen,
- 25 type X, alpha 1 (Col10a1), Rosati R, et al. *Nature Genet* 1994, 8:129–135; P glycoprotein 3 (Pgy3), Schinkel AH, et al. *Cell* 1994, 77:491–502; Yamaguchi sarcoma viral (v-yes) oncogene homolog (Yes), Stein PL, et al. *Genes Dev* 1994, 8:1999–2007; Fc receptor, IgE, high affinity II, alpha polypeptide (Fcer2a), Stief A, et al. *J Immunol* 1994, 152:3378–3390; Pore forming protein (Pfp), Walsh CM, et al. *Proc Natl Acad Sci USA* 1994, 91:10854–10858; CD2 antigen (Cd2), Evans CF, et al. *J Immunol* 1993, 151:6259–6264; Mannose-6-phosphate receptor, cation dependent (M6pr), Koster A, et al. *EMBO J* 1993, 12:5219–5223; Retinoic acid receptor, alpha (Rara), Li E, et al. *Proc*

- Natl Acad Sci USA 1993, 90:1590–1594, Lufkin T, et al. Proc Natl Acad Sci USA 1993, 90:7225–7229; Retinoic acid receptor, gamma (Rarg), Lohnes D, et al. Cell 1993, 73:643–658; Tumor necrosis factor receptor 1 (TNF-R-1) (Tnfr1), Pfeffer K, et al. Cell 1993, 73:457–467; Lectin, galactose binding, soluble 1 (Lgals1), Poirier F, Robertson EJ.
- 5 Development 1993, 119:1229–1236; Synapsin I (Syn1), Rosahl TW, et al. Cell 1993, 75:661–670; Tumor necrosis factor receptor 1 (Tnfr1), Rothe J, et al. Nature 1993, 364:798–802; Beta-2 microglobulin (B2m), Correa I, et al. Proc Natl Acad Sci USA 1992, 89:653–657; CD2 antigen (Cd2), Killeen N, et al. EMBO J 1992, 11:4329–4336; Apolipoprotein E (Apoe), Piedrahita JA, et al. Proc Natl Acad Sci USA 1992, 89:4471–
- 10 4475; Myogenic differentiation 1 (Myod1), Rudnicki MA, et al. Cell 1992, 71:383–390; Tenascin C (Tnc), Saga Y, et al. Genes Dev 1992, 6:1821–1831; Beta-2 microglobulin (B2m), Sanjuan N, et al. J Virol 1992, 66:4587–4590; Neuroblastoma myc-related oncogene 1 (Nmyc1), Stanton BR, et al. Genes Dev 1992, 6:2235–2247; and
- 15 Hemoglobin alpha chain complex (Hba), Popp RA, et al. Genetics 1983, 105:157–167.
- Some preferred single-copy, non-essential genes with no phenotypes of the present invention include, but are not limited to, the following: Moesin (Msn), Doi Y., et al., J Biol Chem 1999, 274:2315–2321; Plasminogen activator inhibitor, type II (Planh2) and Planh1, Dougherty K.M., Proc Natl Acad Sci USA 1999, 96:686–691; Nuclear receptor coactivator 1 (Ncoa1), Qi C, et al. (1999) Proc Natl Acad Sci USA 96:1585–
- 20 1590; Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha and beta (Nfkbia and Nfkbb), Cheng JD, et al. (1998) J Exp Med 6:1055–1062; H19 fetal liver mRNA (H19), Jones BK, et al. (1998) Genes Dev 12:2200–2207; Prion protein (Prnp), Lipp HP, et al. Behav Brain Res 1998, 95:47–54; Centromere autoantigen B (Cenpb), Perez-Castro AV, et al. Dev Biol 1998, 201:135–143; Placentae and embryos
- 25 oncofetal gene (Pem), Pitman JL, et al. Dev Biol 1998, 202:196–214; Externally regulated phosphatase (Ptpr16), Dorfman K, et al. Oncogene 1996, 13:925–931; Transformation related protein 53 (Trp53), Ohashi M, et al. Jpn J Cancer Res 1996, 87:696–701; H1-0 histone (H1fv), Sirotnik AM, et al. Proc Natl Acad Sci U S A 1995, 92:6434–6438; Creatine kinase, mitochondrial 1, ubiquitous (Ckmt1), Steeghs K, et al.
- 30 Biochim Biophys Acta 1995, 1230:130–138; Neuroblastoma ras oncogene (Nras), Umanoff H, et al. Proc Natl Acad Sci USA 1995, 92:1709–1713; Vitronectin (Vtn), Zheng X, et al. Proc Natl Acad Sci U S A 1995, 92:12426–12430; Vimentin (Vim),

- Colucci GE, et al. Cell 1994, 79:679–694; Cellular retinoic acid binding protein I (Crabp1), Gorry P, et al. Proc Natl Acad Sci USA 1994, 91:9032–9036; Retinoic acid receptor beta2 (RARbeta2), Mendelsohn C, et al. Dev Biol 1994, 166:246–258; Retinoic acid receptor, alpha (Rara), Li E, et al. Proc Natl Acad Sci USA 1993, 90:1590–1594,
- 5 Lufkin T, et al. Proc Natl Acad Sci USA 1993, 90:7225–7229; Lectin, galactose binding, soluble 1 (Lgals1), Poirier F, Robertson EJ. Development 1993, 119:1229–1236;
- Myogenic differentiation 1 (Myod1), Rudnicki MA, et al. Cell 1992, 71:383–390; and Tenascin C (Tnc), Saga Y, et al. Genes Dev 1992, 6:1821–1831.

In view of the guidance of the present specification, one of ordinary skill in the art can select similar, suitable, single-copy, non-essential genes in mice and other cell types/organisms.

Assembly of Targeting Cassettes

The targeting cassettes described herein can be constructed utilizing methodologies known in the art of molecular biology (see, for example, Ausubel or Maniatis) in view of the teachings of the specification. As described above, the targeting constructs are assembled by inserting, into a suitable vector backbone, polynucleotides encoding a reporter, such as a light-generating protein, e.g., a luciferase gene, operably linked to a promoter of interest; a sequence encoding a positive selection marker; and, 20 optionally a sequence encoding a negative selection marker. In addition, the targeting cassette contains insertion sites such that sequences targeting a single-copy, non-essential gene can be readily inserted to flank the sequence encoding positive selection marker and luciferase-encoding sequence.

A preferred method of obtaining polynucleotides, suitable regulatory sequences (e.g., promoters) is PCR. General procedures for PCR as taught in MacPherson et al., PCR: A PRACTICAL APPROACH, (IRL Press at Oxford University Press, (1991)). PCR conditions for each application reaction may be empirically determined. A number of parameters influence the success of a reaction. Among these parameters are annealing temperature and time, extension time, Mg²⁺ and ATP concentration, pH, and the relative 30 concentration of primers, templates and deoxyribonucleotides. Exemplary primers are described below in the Examples. After amplification, the resulting fragments can be

detected by agarose gel electrophoresis followed by visualization with ethidium bromide staining and ultraviolet illumination.

In one embodiment, PCR can be used to amplify fragments from genomic libraries. Many genomic libraries are commercially available. Alternatively, libraries 5 can be produced by any method known in the art. Preferably, the organism(s) from which the DNA is has no discernible disease or phenotypic effects. This isolated DNA may be obtained from any cell source or body fluid (e.g., ES cells, liver, kidney, blood cells, buccal cells, cerviovaginal cells, epithelial cells from urine, fetal cells, or any cells present in tissue obtained by biopsy, urine, blood, cerebrospinal fluid (CSF), and tissue 10 exudates at the site of infection or inflammation). DNA is extracted from the cells or body fluid using known methods of cell lysis and DNA purification. The purified DNA is then introduced into a suitable expression system, for example a lambda phage.

Another method for obtaining polynucleotides, for example, short, random nucleotide sequences, is by enzymatic digestion. As described below in the Examples, 15 short DNA sequences generated by digestion of DNA from vectors carrying genes encoding luciferase (yellow green or red).

Polynucleotides are inserted into vector genomes using methods known in the art. For example, insert and vector DNA can be contacted, under suitable conditions, with a restriction enzyme to create complementary or blunt ends on each molecule that can pair 20 with each other and be joined with a ligase. Alternatively, synthetic nucleic acid linkers can be ligated to the termini of a polynucleotide. These synthetic linkers can contain nucleic acid sequences that correspond to a particular restriction site in the vector DNA. Other means are known and, in view of the teachings herein, can be used.

25 The final constructs can be used immediately (e.g., for introduction into ES cells), or stored frozen (e.g., at -20°C) until use. Preferably, the constructs are linearized prior to use, for example by digestion with suitable restriction endonucleases.

Transgenic Animals

The targeting constructs containing the light generating protein coding sequences (e.g., luciferase genes) are introduced into a pluripotent cell (e.g., ES cell, Robertson, E. J., In: *Current Communications in Molecular Biology*, Capecchi, M. R. (ed.), Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), pp. 39-44). Suitable ES cells may be derived or isolated from any species or from any strain of a particular species. Although not required, the pluripotent cells are typically derived from the same species as the intended recipient. ES cells may be obtained from commercial sources, from International Depositories (e.g., the ATCC) or, alternatively, may be obtained as described in Robertson, E. J., *supra*. Examples of clonally-derived ES cells lines include 129/SVJ ES cells, RW-4 and C57BL/6 ES cells (Genome Systems, Inc.).

ES cells are cultured under suitable conditions, for example, as described in Ausubel et al., section 9.16, *supra*. Preferably, ES cells are cultured on stromal cells (such as STO cells (especially SNC4 STO cells) and/or primary embryonic fibroblast cells) as described by E. J. Robertson, *supra*, pp 71-112. Culture media preferably includes leukocyte inhibitory factor ("lif") (Gough, N. M. et al., *Reprod. Fertil. Dev.* 1:281-288 (1989); Yamamori, Y. et al., *Science* 246:1412-1416 (1989), which appears to help keep the ES cells from differentiating in culture. Stromal cells transformed with the gene encoding lif can also be used.

The targeting constructs are introduced into the ES cells by any method which will permit the introduced molecule to undergo recombination at its regions of homology, for example, micro-injection, calcium phosphate transformation, or electroporation (Toneguzzo, F. et al., *Nucleic Acids Res.* 16:5515-5532 (1988); Quillet, A. et al., *J. Immunol.* 141:17-20 (1988); Machy, P. et al., *Proc. Natl. Acad. Sci. (U.S.A.)* 85:8027-8031 (1988)). The construct to be inserted into the ES cell must first be in the linear form. Thus, if the knockout construct has been inserted into a vector as described above, linearization is accomplished by digesting the DNA with a suitable restriction endonuclease selected to cut only within the vector sequence and not within the knockout construct sequence. If the ES cells are to be electroporated to insert the construct, the ES cells and construct DNA are exposed to an electric pulse using an electroporation machine and following the manufacturer's guidelines for use. After electroporation, the ES cells are typically allowed to recover under suitable incubation conditions. The cells

are then cultured under conventional conditions, as are known in the art, and screened for the presence of the construct.

Screening and selection of those cells into which the targeting construct has been integrated can be achieved using the positive selection marker and/or the negative

5 selection marker in the construct. In preferred embodiments, the construct contains both positive and negative selection markers. In one aspect, methods which rely on expression of the selection marker are used, for example, by adding the appropriate substrate to select only those cells which express the product of the positive selection marker or to eliminate those cells expressing the negative selection marker. For

10 example, where the positive selection marker encodes neomycin resistance, G418 is added to the transformed ES cell culture media at increasing dosages. Similarly, where the negative selection marker is used, a suitable substrate (*e.g.*, gancyclovir if the negative selection marker encodes HSV-TK) is added to the cell culture. Either before or after selection using the appropriate substrate, the presence of the positive and/or

15 negative selection markers in a recipient cell can also be determined by other methods, for example, hybridization, detection of radiolabelled nucleotides, PCR and the like. In preferred embodiments, cells having integrated targeting constructs are first selected by adding the appropriate substrate for the positive and/or negative selection markers. Cells that survive the selection process are then screened by other methods, such as PCR or

20 Southern blotting, for the presence of integrated sequences.

After suitable ES cells containing the construct in the proper location have been identified, the cells can be inserted into an embryo, preferably a blastocyst. The blastocysts are obtained by perfusing the uterus of pregnant females. In one embodiment, the blastocysts are obtained from, for example, the FVB/N strain of mice and the ES cells

25 are obtained from, for example, the C57BL/6 strain of mice. Suitable methods for accomplishing this are known to the skilled artisan, and are set forth by, *e.g.*, Bradley et al., (1992) Biotechnology, 10:534-539. Insertion into the embryo may be accomplished in a variety of ways known to the skilled artisan, however a preferred method is by microinjection. For microinjection, about 10-30 ES cells are collected into a micropipet

30 and injected into embryos that are at the proper stage of development to permit integration of the foreign ES cell containing the construct into the developing embryo.

The suitable stage of development for the embryo used for insertion of ES cells is species dependent, in mice it is about 3.5 days.

While any embryo of the right stage of development is suitable for use, it is preferred that blastocysts are used. In addition, preferred blastocysts are male and, 5 furthermore, preferably have genes encoding a coat color that is different from that encoded by the genes ES cells. In this way, the offspring can be screened easily for the presence of the knockout construct by looking for mosaic coat color (indicating that the ES cell was incorporated into the developing embryo). Thus, for example, if the ES cell line carries the genes for black fur, the blastocyst selected will carry genes for white or 10 brown fur.

After the ES cell has been introduced into the blastocyst, the blastocyst is typically implanted into the uterus of a pseudopregnant foster mother for gestation. Pseudopregnant females are prepared by mating with vasectomized males of the same species and successful implantation usually must occur within about 2-3 days of mating.

15 Offspring are screened initially for mosaic coat color where the coat color selection strategy has been employed. Southern blots and/or PCR may also be used to determine the presence of the sequences of interest. Mosaic (chimeric) offspring are then bred to each other to generate homozygous animals. Homozygotes and heterozygotes may be identified by Southern blotting of equivalent amounts of genomic DNA from 20 mice that are the product of this cross, as well as mice that are known heterozygotes and wild type mice. Alternatively, Northern blots can be used to probe the mRNA to identify the presence or absence of transcripts encoding either the replaced gene, the light generating protein coding sequence (e.g., luciferase gene), or both. In addition, Western blots can be used to assess the level of expression of the luciferase protein with an 25 antibody against the luciferase gene product. Finally, *in situ* analysis (such as fixing the cells and labeling with antibody) and/or FACS (fluorescence activated cell sorting) analysis of various cells from the offspring can be conducted using suitable (e.g., anti-luciferase) antibodies to look for the presence or absence of the targeting construct.

In one embodiment of the present invention, the animals are from the C57BL/6 30 mouse strain. This strain develops a variety of tumors and has been used to develop a number of tumor cell lines, for example, B16 melanoma cells (including, B16F10, B16D5, and B16F1), Lewis lung carcinoma cells (including, LLC, LLC-h59), T241

mouse fibrosarcoma cells, RM-1 and pTC2 mouse prostate cancer cells, and MCA207 mouse sarcoma cells. These cell lines have been extensively used for *in vivo* tumor biology studies after injection into C57BL/6 mice. The generated targeted transgenic mice in the Examples are in C57BL/6 genetic background and these animals are suitable
5 for injection or implantation of such tumor cells, as well as other tumor cells described in literature that are immunocompetent for C57BL/6 mice. Thus, the transgenic animals can then be used, for example, to monitor, *in vivo*, tumor progression (*e.g.*, growth) and the efficacy of therapies on tumor regression. For example, where the transgenic animal is tumor-susceptible, it is monitored for expression of a reporter, *e.g.*, luciferase, which is
10 indicative of tumorigenesis and/or angiogenesis. The monitoring of expression of luciferase reporter expression cassettes using non-invasive whole animal imaging has been described (Contag, C. et al, U.S. Patent No. 5,650,135, July 22, 1997; Contag, P., et al, *Nature Medicine* 4(2):245-247, 1998; Contag, C., et al, *OSA TOPS on Biomedical Optical Spectroscopy and Diagnostics* 3:220-224, 1996; Contag, C.H., et al,
15 *Photochemistry and Photobiology* 66(4):523-531, 1997; Contag, C.H., et al, *Molecular Microbiology* 18(4):593-603, 1995). Such imaging typically uses at least one photo detector device element, for example, a charge-coupled device (CCD) camera.

The transgenic animals described herein can also be used to determine the effect of an analyte (*e.g.*, therapy), for example on tumor progression where the promoter
20 induces light generating protein (*e.g.*, luciferase) expression when a tumor develops. Methods of administration of the analyte include, but are not limited to, injection (subcutaneously, epidermally, intradermally), intramucosal (such as nasal, rectal and vaginal), intraperitoneal, intravenous, oral or intramuscular. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal
25 applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. For example, the analyte of interest can be administered over a range of concentration to determine a dose/response curve. The analyte may be administered to a series of test animals or to a single test animal (given that response to the analyte can be cleared from the transgenic animal).

30 The following examples are intended only to illustrate the present invention and should in no way be construed as limiting the subject invention.

EXAMPLES

Example 1
Generating the Targeting Cassette and Vector

5

A. Creation of the Backbone Vector

- pTK53: The 0.5 kb mouse phosphoglycerate kinase 1 promoter was amplified with PGK primers (PGKF, SEQ ID NO:1:
ATCGAATTCTACCGGGTAGGGGAGGCGCTT; PGKR, SEQ ID NO:2:
10 GGCTGCAGGTCAAAGGCCGGAGATGAGG) using mouse genomic DNA (Genome Systems, Inc., St. Louis, MO) as template. This fragment was then double digested with EcoRI and PstI and cloned into the pKS vector (Stratagene, La Jolla, California) which was linearized with the same enzymes. The neomycin gene was amplified with NeoF (SEQ ID NO:3:
15 ACCTGCAGCCAATATGGGATCGGCCATTGAAC) and NeoR (SEQ ID NO:4:
GGATCCGGGCCGCCCCAGCTGGTTCTTCCGCCTC) primers using pNTKV1907 (Stratagene) as a template. The 1.1 kb PCR fragment was double digested with PstI and BamHI and cloned into the pKS-PGK vector which was linearized with the same enzymes. This pKS-PGK-Neo vector was used to clone thymidine kinase gene as follows. Primers TKF (SEQ ID NO: 5:
GGATCCTCTAGAGTCGAGCAGTGTGGTTT) and TKR (SEQ ID NO:6:
15 GAGCTCCGTAGTCAGGTTAGTCGTCCG) were used to amplify the TK gene from pNTKV1907 (Stratagene). The amplified 2kb fragment was then digested with BamHI and SacI and cloned into pKS-PGK-Neo vector that was linearized with the same enzymes. This constructed vector was designated as pTK. A synthetic linker F5R5 was made after annealing of two primers (forward primer, F5R51, SEQ ID NO: 7:
GTACATTTAAATCCTGCAGG; reverse primer, F5R52, SEQ ID NO:8:
25 AGCTCCTGCAGGATTAAAT). This linker was inserted between Asp718I and HindIII sites of pTK and the new construct was designated pTK5. A second synthetic linker F3R3 was made by annealing of two primers (forward primer, F3R31, SEQ ID NO:9:
GGCCCGGGCTTAATTAATGCATCATGGTACCGTTAACCGCGGCCGCAAG
30 CTTGTCGACGGCGCGCCGGCC; reverse primer, F3R32, SEQ ID NO:10:
GGCCCGGGCTTAATTAATGCATCATGGTACCGTTAACCGCGGCCGCAAG
CTTGTCGACGGCGCGCCGGCC; reverse primer, F3R32, SEQ ID NO:10:

GATCGGCCGGCCGGCGCGCCGTCGACAAGCTTGCAGCCGCGTTAACGGTA
CCATATGATGCATTAATTAAGCCCG).). This linker was inserted between NotI and
BamHI sites of pTK and the new construct was designated pTK53. Schematics of the
vectors are shown are shown in Figure 1.

5

B. Introduction of Luciferase

pTK-LucYG and pTK-LucR: The yellow green luciferase gene was isolated
from pGL3 vector (Promega) as a HindIII-SalI fragment and was cloned into pGK53 that
was linearized with the same enzymes. The new construct was designated pTK-LucYG
10 (8931 bp), shown in Figure 2.

The red luciferase gene was isolated from pGL3-red vector (Dr. Christopher
Contag, Stanford University, Stanford, Calif.) as a HindIII-SalI fragment and was cloned
into pGK53 that was linearized with the same enzymes. The new construct was
designated pTK-LucR (8931 bp), shown in Figure 2.

15

Example 2**Insertion of Targeting Sequences**

A. Generation of vitronectin targeting vector: The targeting construct
20 pTKLR-Vn was generated by inserting vitronectin (VN) DNA sequences into pTK-LucR
vector.

Vitronectin (VN) is an abundant glycoprotein present in plasma and the
extracellular matrix of most tissues. In a previous study, it was shown that heterozygous
mice carrying one normal and one null VN allele and homozygous null mice completely
25 deficient in vitronectin demonstrate normal development, fertility, and survival. This
suggests that VN is not essential for cell adhesion and migration during normal mouse
development (Zheng, X., et al., Proc Natl Acad Sci U S A 1995 92:12426-30). Mouse
vitronectin genomic DNA sequence of 5004 bp was obtained from GenBank database
(Accession number X72091). Based on this sequence, a 1.63 kb 3'end vitronectin
30 fragment was amplified (reverse primer, VN1R, SEQ ID NO:11:
CTGTATTAAATCTGCCACCTATTCAGGACAGTAGTC; forward primer,
VN1F, SEQ ID NO:12: CCAATGCATCAACCCAGCCAGGAGGTGCG) using
mouse C57BL/6 genomic DNA as template (Genome Systems, Inc., St. Louis, MO).

This fragment was digested with *Swal* and *NsiI* and cloned into pTK-LucR (linearized with *Swal* and *SbfI*). This construct was designated as pTK-LucR3. Subsequently, a 2.35 kb 5'end vitronectin fragment was amplified (reverse primer, VN2R, SEQ ID NO:13: AACCGTCGACTTCGGAGATGTTGGGGATAACCAGG; forward primer,

5 VN2F, SEQ ID NO:14:

TTGGCGGCCCATAGAGAAGAGACACCAAAGGCACGCTC) using mouse C57BL/6 genomic DNA as template. This fragment was digested with *SalI* and *AscI* and cloned into pTK-LucR vector that was linearized with *SalI* and *AscI*. This construct was designated as pTKLR-Vn. Figure 3 shows the restriction map of pTKLR-Vn vector. The 10 polylinker between the neomycin gene and red luciferase gene is used to insert the VEGF promoter or other promoters of interests. The predicted homologous recombination between pTKLR-Vn and vitronectin gene is illustrated in Figure 3A. Upon insertion of the VEGF-LucR transgene cassette, the endogenous vitronectin gene is destroyed. Figure 3B shows the genomic DNA sequence of VN.

15

B. Generation of Fos targeting vector: The targeting construct pTKLG-Fos was generated by inserting FosB DNA sequences into pTK-LucYG vector.

FosB is one of the members of the Fos family. It plays a functional role in transcriptional regulation. It has been shown that FosB mice are born at a normal 20 frequency, are fertile and present no obvious phenotypic or histologic abnormalities (Gruda et al (1996) *Oncogene* 12:2177-2185). A 28.8 kb genomic region that contains mouse FosB DNA sequence was obtained from GenBank database (Accession number AF093624).

Using this sequence, a 1.71 kb 5'end FosB fragment was amplified (forward 25 primer, FosB1F, SEQ ID NO:15:
CTGTATTAAATCCGTTCTCACTGTGCCTGTGTC; reverse primer, FosB1R, SEQ ID NO:16: GTCTCCTGCAGGCTTCCTCCTCCTTGTCCCTGCG) using mouse C57BL/6 genomic DNA as template. This fragment was digested with *Swal* and *SbfI* and cloned into pTK-LucYG vector that was linearized with *Swal* and *SbfI*. This construct 30 was designated as pTK-LucYG3. Subsequently, a 1.58 kb 3'end FosB fragment was amplified (forward primer, FosB2F, SEQ ID NO:17:
AACCGTCGACGGATGGGATTGACCCCCAGCCCTC; reverse primer, FosB2R,

SEQ ID NO:18: TTGGCGCGCCCTTGCCTCCACCTCTCAAATGC) using mouse C57BL/6 genomic DNA as template. This fragment was digested with *Sall* and *AscI* and cloned into pTK-LucYG vector that was linearized with *Sall* and *AscI*. This construct was designated as pTKLG-Fos (Figure 4). The polylinker between the neomycin gene 5 and red luciferase gene is used to insert the VEGFR2 promoter (Example 3, Figure 5A), Tie2 promoter (Example 3, Figure 5B), as well as, other promoters of interests. The predicted homologous recombination between the targeting vector bearing the VEGFR2 promoter (Figure 5A) or the Tie2 promoter (Figure 5B) and FosB gene is also illustrated. As shown in the Figures, the VEGFR2-LucYG transgene cassette and Tie2-LucYG 10 transgene cassette is inserted downstream of FosB gene translational stop signal. Therefore, the targeted transgenic mice should still have a functional FosB gene while expressing the transgenes. Figure 4B shows the DNA sequence of FosB.

Example 3

15 Insertion of Promoter Sequences of Interest

A. pTKLR-Vn/VEGF: Mouse VEGF genomic DNA sequence of 2240 bp that contains a partial VEGF promoter region was obtained from GenBank (accession number: U41383). Accordingly, primers were designed to amplify a 0.69 kb (VF1-VR1A; Table 1) and a 0.98 kb fragment (VF2-VR2; Table 1). It was confirmed that 20 each pair of primers can amplify the predicted product using mouse129SvJ genomic DNA as template.

Table 1

Name	Seq Id No	Sequence
VF1	19	ACCTC ACTCT CCTGT CTCCC CTGAT TCCCA A
VR1A	20	GCTCT GGCGG TCACC CCCAA AAGCA
VF2	21	CCCTT TCCAA GACCC GTGCC ATTTG AGC
VR2	22	ACTTT GCCCC TGTCC CTCTC TCTGT TCGC
KF1	23	GCTGC GTCCA GATT GCTCT CAGAT GCG
KR1	24	TTCTC AGGCA CAGAC TCCTT CTCCG TCCCT
KF2	25	CAGAT GGACG AGAAA ACAGT AGAGG CGTTG GC
KR2	26	GAGGA CTCAG GGCAG AAAGA GAGCG
TF3	27	AGCTT AGCCT GCAAG GGTGG TCCTC ATCG
TF2	28	CAAAT GCACC CCAGA GAACA GCTTA GCCTG C
TR1	29	GCTTT CAACA ACTCA CAACT TTGCG ACTTC CCG

Conditions for PCR amplification are shown in Figure 6. These primers were
5 used for PCR screening of mouse 129/SvJ genomic DNA BAC (bacterial artificial chromosome) library (Genome Systems, Inc., St. Louis, MO). The library, on average, contained inserts of 120 kb with sizes ranging between 50 kb to 240 kb. A large genomic DNA fragment that contained VEGF promoter region was obtained. Southern blot analysis was performed to map the VEGF promoter region. A unique HindIII
10 restriction site was mapped approximately 7.8 kb upstream of the ATG translational start codon of the VEGF gene. The sequences between HindIII and ATG translational start codon are inserted into the polylinker of pTKLR-Vn vector to finish the construction of targeting vector that contains VEGF-LucR transgene (Figure 3A).

15 **B. pTKLG-Fos/VEGFR2**

A mouse VEGFR2 genomic DNA sequence of 1079 bp which contains a partial VEGFR2 promoter region was published previously (Ronicke, et al., (1996) *Cir. Res.* 79:277-285). Accordingly, primers were designed to amplify a 0.45 kb (KF1-KR1A; Table 1) and a 0.58 kb fragment (KF2-KR2; Table 1). It was confirmed that each pair of
20 primers can amplify the predicted product using mouse 129SvJ genomic DNA as

template. DNA sequences for these primers are shown in Table 1 above and PCR amplification conditions are shown in Figure 6. These primers were used for PCR screening of mouse 129/SvJ genomic DNA BAC library. From the screening, a BAC clone that contained a large genomic DNA fragment was obtained. Based on the published restriction map of VEGFR2, a 4.5 kb HindIII-XbaI fragment that covers the VEGFR2 promoter region was subcloned from the VEGFR2 BAC clone into the pBluescriptSK vector (Stratagene, La Jolla, CA) that was linearized with HindIII and XbaI. The VEGFR2 promoter sequences of 4.1 kb, spanning from a HindIII site to the ATG translational start codon, are subcloned into the polylinker of pTKLG-Fos vector to construct the targeting vector that contains VEGFR2-LucYG transgene (Figure 5A).

C. pTKLG-Fos/Tie2

Mouse Tie2 genomic DNA sequence of 477 bp which contain a partial Tie2 promoter region has been published previously (Fadel et al (1998) *Biochem. J.* 330(Pt 1):335-343). Accordingly, primers were designed to amplify a 0.45 kb (TF3-TR1; Table 1) and a 0.47 kb fragment (TF2-TR1; Table 1). It was confirmed that each pair of primers amplified the predicted product using mouse 129SvJ genomic DNA as template. DNA sequences for these primers are shown in Table 1 above. PCR amplification conditions are shown in Figure 6. These primers are used for PCR screening of mouse 129SvJ genomic DNA BAC library. From the screening, a BAC clone containing a large genomic DNA fragment of the Tie2 promoter region was obtained. Based on the published Tie2 genomic DNA restriction map (see, Dumont et al., *supra*), a 10.5 kb Asp718-EcoRV fragment containing the Tie2 promoter region was subcloned ifrom the Tie2 BAC clone into the pSK vector that was linearized with Asp718 and EcoRV. The Tie2 promoter sequences of about 6.8 kb, spanning from the Asp718 site to the ATG translational start codon is subcloned into the polylinker of pTKLG-Fos vector to construct the Tie2-LucYG targeting vector (Figure 5B).

Example 4**Generation of Transgenic Mice Carrying the Constructs of the Present
Invention**

5 **A. General Procedure:** Figure 7 depicts a generalized description of generation of transgenic mice using the targeted transgenic vectors described in Example 3. Details regarding embryonic stem (ES) cell culture, transfection, blastocyst injection and implantation to a pseudopregnant foster are described, for example, in Hogan et al (1994) "Manipulating the Mouse Embryo, A Laboratory Manual. Second Edition", Cold Spring

10 Harbour Laboratory Press.

After construction the targeted transgenic construct are transfected into C57BL/6 embryonic stem (ES) cells. (Genome System Inc., Genome Systems, Inc., St. Louis, MO) through electroporation. The antibiotic G418 is used to select for cells in which the DNA construct containing the Neo gene is integrated, either randomly or by homologous recombination. The nucleoside analog gancyclovir is converted by TK to a cytotoxic derivative. DNA that has integrated by homologous recombination lose the TK gene and are resistant to the drug, whereas cells that have incorporated the DNA randomly are likely to retain the TK gene. Thus, cells containing random integrations into a chromosomal location that allows the expression of the TK gene are killed. The G418 and gancyclovir resistant clones are then be screened by PCR and Southern blot analysis and those that have homologous DNA recombination is used for FVB/N blastocyst injection (Genome System, Inc.). Between 4-16 blastocysts are transferred to the uterus of a pseudopregnant foster mother. The pups are typically born 17 days after the transfer. Either random bred mice or F1 hybrid mice make suitable recipients. Females of certain random-bred stocks (*e.g.*, CD1 mice, from Charles River Laboratories) have very large ampullae, which makes oviduct transfer easier. These mice also generally make good mothers. Alternatively, F1 hybrid females (*e.g.*, B6 x CBA F1) can be used as recipients. Although their ampullae are smaller, make exceptionally good mothers, rearing litters as small as two pups. See, for example, Hogan et al. (1994), *supra*.

B. Screening for homologous DNA recombination positive ES cells

- 1). **pTKLG-Fos/VEGFR2:** Analysis of homologous DNA recombination between pTKLG-Fos/VEGFR2 targeting vector and the FosB gene is carried out using Southern blot analysis as shown in Figure 8. Genomic DNA prepared from G418 resistant ES cells is digested with PvuII and probed with probe A to confirm the 5'end DNA recombination. PvuII digestion of DNA bearing homologous recombination reveals two separate bands of 8.2 and 4.0 kb, whereas digestion of DNA from homologous recombination negative clones reveals only the 8.2 kb band. The 3'end of DNA recombination is tested by hybridizing NotI digested DNA with probe B. NotI digestion of DNA bearing homologous recombination will reveal two separate bands of >8.2kb and 5.0 kb, whereas digestion of DNA from homologous recombination negative clones will only reveal the >8.2 kb band. Once homologous DNA recombination is confirmed, positive clones is selected for FVB/N blastocyst injection.
- 15 2) **pTKLG-Fos/Tie2:** Analysis of homologous DNA recombination between pTKLG-Fos/Tie2 targeting vector and the FosB gene is analyzed by Southern blot in a similar manner as described above for pTKLG-Fos/VEGFR2. Once homologous DNA recombination is confirmed, positive clones are selected for FVB/N blastocyst injection.
- 20 3) **PTKLR-Vn/VEGF:** Analysis of homologous DNA recombination between pTKLR-Vn/VEGF targeting vector and the vitronectin gene is analyzed by PCR. DNA primers designed according to the predicted homologous recombination, are listed in Table 2.

Table 2
PCR primers for analysis of homologous DNA recombination between pTKLR-
Vn/VEGF targeting vector and the vitronectin gene

5

5'end primers	
F51 5'- CCCAGTGTCTCTGATTAGGGAGAGCACCTGAG -3'	SEQ ID NO:30
R51 5'- CCAGACTGCCTGGGAAAAGCGCCTC -3'	SEQ ID NO:31
F52 5'- CAGTGAGAGTCTTCTCTGTCCCTCAATCGGTTCTG -3' SEQ ID NO:32	
R52 5'- TGGATGTGGAATGTGTGCGAGGCCAG -3'	SEQ ID NO:33
3'end primers	
F31 5'- AATCAAAGAGGCGAACTGTGTGAGAGGTCC -3'	SEQ ID NO:34
R31 5'- CGGCTCCCCAAAATGTGGAAGCAAGC -3'	SEQ ID NO:35
F32 5'- GAATCCATCTTGCTCCAACACCCCCAACATC -3'	SEQ ID NO:36
R32 5'- CGCCTCCTCTCCCCAGTCTCCCCTTG -3'	SEQ ID NO:37

- Primers F51-R51 and F52-R52 amplify a 1799 bp and a 1841 bp DNA fragment respectively from the 5'end of the transgene that is integrated into the vitronectin site through homologous DNA recombination, whereas primers F31-R31 and F32-R32 amplify a 3549 bp and a 3428 bp DNA fragment respectively from the 3'end of the transgene that is integrated into the vitronectin site through homologous DNA recombination. Clones that allow successful amplification of both the 5'end and 3'end of the integrated transgene are selected for FVB/N blastocyst injection.

15

C. Analysis of chimeric mice

- The pups developed from injected blastocysts contain chimeras, as can be identified by their agouti coat color when an ES cell derived from a mouse having a dark coat color (e.g., C57BL/6) is injected into the blastocyst of a light coat color animal (e.g., FVB/N, genotype B/B). DNA analysis (e.g., Southern blotting, PCR) is conducted to further confirm the presence of the transgene in these pups as described above in Section B. These animals may be obtained commercially, for example from The Jackson Laboratory, Bar Harbor, MN.

D. Generating targeted transgenic C57BL/6 mice with white coat color

Breeding of the chimeric mice generates homozygous targeted transgenic mice, as depicted in Figure 9. The targeted mice are used to monitor gene expression through the measurement of luciferase mediated light emission from the mice. In a preferred embodiment, the targeted mouse has a light coat color (e.g., white coat color), because the black colored coat (an example of a dark coat color) of C57BL/6 mice can absorb light emitted from the body and may interfere with the sensitivity of the bioluminescence assay. An inbred mouse strain C57BL/6-Tyr C2j/+ strain (Jackson Laboratory, Bar Harbor, MN) is available for this purpose. This strain of mice have white color coat, yet they still have the same genetic background as C57BL/6 mice except that the gene responsible for the black coat color is mutated. Unfortunately, C57BL/6-Tyr C2j/+ ES cells are not currently available. Therefore, the designed breeding program illustrated in Figure 9 is aimed to generate mice that are homozygous for the target transgene and have white coat color. C57BL/6 ES cells are prepared as described above and introduced into a suitable blastocyst (e.g., from the FVB/N strain of mice). The blastocysts are implanted into a foster mother. Chimeric mice are shown in Figure 9 as white animals with black and green patches. Chimeric animals are bred with C57BL/6-Tyr C2j/+ mice to create F1 hybrids. Subsequent breeding of the F1 hybrids generates several type of mice, including the one that is homozygous for the target transgene and has a white coat color (shown in Figure 9 as b/b; L/L), which is used for *in vivo* gene regulation monitoring.

A C57BL/6 mouse and a C57BL/6-Tyr C2j/+ mouse are considered to be substantially isogenic. Accordingly, the method of the present invention exemplified in Figure 9 provides a means for generating breeding groups of substantially isogenic mice in a selected genetic background carrying at least one transgene of interest.

E. Dual luciferase targeted transgenic mice

As described above, two targeting vectors are generated. PTKLR-Vn carries a red luciferase gene and is targeted into vitronectin locus. PTKLG-Fos carries a yellow-green luciferase gene and is targeted into FosB locus. A number of promoters, including VEGF promoter, VEGFR2 promoter, and Tie2 promoter are cloned into these vectors, as described above. Subsequently three type of targeted transgenic mice are generated.

VEGF mice carry VEGF promoter-red luciferase transgene (VEGF-LucR) integrated into vitronectin locus. VEGFR2 mice carry VEGFR2 promoter-yellow-green luciferase (VEGFR2-LucYG) transgene integrated into FosB locus. Tie2 mice carry Tie2 promoter-yellow-green luciferase (Tie2-LucYG) transgene integrated into FosB locus. Through a breeding program illustrated in Figure 10, dual luciferase targeted transgenic mice are produced, carrying both of the VEGF-LucR and the VEGFR2-LucYG transgenes. The degradation of luciferin by yellow-green luciferase and red luciferase generates lights that emit at 540 nM and 610 nM respectively. These wavelengths of light are measured individually using a photo-counting camera (intensified CCD). Therefore, both VEGF expression and VEGFR2 expression, for example, can then be monitored in the same mouse at the same time.

As is apparent to one of skill in the art, various modification and variations of the above embodiments can be made without departing from the spirit and scope of this invention. These modifications and variations are within the scope of this invention.

CLAIMS

What is claimed is:

1. A vector for use in generating a transgenic non-human mammal, said mammal having at least one single-copy, non-essential gene in its genome, said vector comprising
 - (a) a first selectable marker and a reporter expression cassette, said reporter expression cassette comprising a transcriptional promoter element operably linked to a light-generating protein coding sequence, and
 - (b) targeting polynucleotide sequences homologous to a single-copy, non-essential gene in said mammal's genome, said targeting polynucleotide sequences flanking (a), wherein (i) the length of the targeting polynucleotide sequences are sufficient to facilitate homologous recombination between the vector and the single-copy, non-essential gene, and (ii) said transcriptional promoter element is heterologous to the single-copy, non-essential gene.
2. The vector of claim 1, wherein said first selectable marker provides a positive selection.
3. The vector of claim 2, wherein said first selectable marker is selected from the group consisting of neomycin phosphotransferase II, xanthine-guanine phosphoribosyltransferase, hygromycin-B-phosphotransferase, chloramphenicol acetyltransferase, and adeninephosphoribosyl transferase.
4. The vector of claim 3, wherein the first selectable marker is neomycin phosphotransferase II.
5. The vector of any of claims 1-4, further comprising a second selectable marker, wherein at least one target polynucleotide sequence is located between said second selectable marker and (a).
6. The vector of claim 5, wherein said second selectable marker provides a negative selection.

7. The vector of claim 6, wherein said second selectable marker is selected from the group consisting of adenosine deaminase, thymidine kinase, and dihydrofolate reductase.

8. The vector of any of claims 1-7, wherein the transcriptional promoter element is selected from the group consisting of an inducible promoter, a repressible promoter, and a constitutive promoter.

9. The vector of claim 8, wherein the transcriptional promoter element is selected from the group consisting of VEGF, VEGFR, and TIE2.

10. The vector of any of claims 1-9, wherein the sequences encoding the light-generating protein are obtained from either prokaryotic or eucaryotic sources.

11. The vector of claim 10, wherein the light generating protein is a luciferase.

12. The vector of any of claims 1-11, wherein said reporter expression cassette further comprises other control elements.

13. The vector of claim 12, wherein said control elements are selected from the group consisting of transcription enhancer elements, transcription termination signals, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.

14. The vector of any of claims 1-11, wherein said vector is circular.

15. The vector of claim 14, wherein said vector contains at least one restriction site whose cleavage results in a linear vector having the following arrangement of elements: targeting polynucleotide sequence - (a) - targeting polynucleotide sequences.

16. The vector of claim 5, wherein said vector is circular.

17. The vector of claim 16, wherein said vector contains at least one restriction site whose cleavage results in a linear vector having the following arrangement of elements: target polynucleotide sequence - (a) - targeting polynucleotide sequences - (second selectable marker).

18. The vector of any of claims 1-17, wherein the coding sequences of the reporter expression cassette comprise codons that are optimal for expression in a host system into which the expression cassette is to be introduced.

19. The vector of claim 18, wherein said mammal is a rodent.

20. The vector of claim 19, wherein said mammal is a mouse.

21. The vector of any of claims 1-20, wherein said targeting polynucleotide sequences from single-copy, non-essential genes are selected from the group consisting of vitronectin, *fosB*, and galactin 3.

22. A method of producing a transgenic, non-human mammal, said mammal having at least one single-copy, non-essential gene in its genome, comprising transfecting an embryonic stem cell of said mammal with a linear vector comprising

(a) a first selectable marker and a reporter expression cassette, said reporter expression cassette comprising a transcriptional promoter element operably linked to a light-generating protein coding sequence, and

(b) targeting polynucleotide sequences homologous to a single-copy, non-essential gene in said mammal's genome, said targeting polynucleotide sequences flanking (a), wherein (i) the length of the polynucleotide sequences are sufficient to facilitate homologous recombination between the vector and the single-copy, non-essential gene, and (ii) said transcriptional promoter element is heterologous to the single-copy, non-essential gene;

selecting embryonic stem cells which each have said first selectable marker and reporter expression cassette integrated into its genome;
injecting said embryonic stem cells into a host embryo,
implanting said embryo in a foster mother,
maintaining said foster mother under conditions which allow production of an offspring that is a transgenic, non-human mammal carrying said reporter expression cassette.

23. The method of claim 22, wherein said offspring is capable of germline transmission of said reporter expression cassette.

24. The method of claim 23 further comprising breeding said offspring with a mammal, wherein the mammal is substantially isogenic with the embryonic stem cells, wherein said breeding yields transgenic F1 offspring carrying said reporter cassette.

25. The method of claim 24, further comprising breeding a first F1 offspring carrying said reporter cassette with a second F1 offspring carrying said reporter cassette, wherein said breeding yields transgenic F2 offspring carrying said reporter cassette.

26. The method of any of claims 22-25, wherein said mammal is a mouse.

27. The method of claim 26, wherein said embryonic stems cells are derived from a mouse having a dark coat color.

28. The method of claim 27, wherein said mammal substantially isogenic with the embryonic stem cells has a light coat color.

29. The method of claim 28, wherein said F2 offspring carrying said reporter cassette has a light coat color.

30. The method of claim 29, wherein said embryonic stems cells are derived from a C57BL/6 mouse having a dark coat color, and said mammal substantially

isogenic with the embryonic stem cells is a C57BL/6-Tyr C2j/+ mouse having a light coat color.

31. The method of any of claims 22-30, wherein the light generating protein is a luciferase.

32. A transgenic, non-human mammal, comprising at least one single-copy, non-essential gene in its genome, wherein (i) at least a portion of at least one single-copy, non-essential gene is replaced by polynucleotide sequences heterologous to the gene, such that the gene cannot produce a functional gene product, and (ii) said polynucleotide sequences comprise a first expression cassette which has been introduced into said mammal or an ancestor of said mammal, at an embryonic stage, said first expression cassette comprising

a first selectable marker,

a first transcriptional promoter element heterologous to the gene, and

light-generating protein coding sequences, wherein said light-generating protein coding sequences are operably linked to said promoter element.

33. The transgenic, non-human mammal of claim 32, wherein the single-copy, non-essential gene is selected from the group consisting of vitronectin, *fosB*, and galactin 3.

34. The transgenic, non-human mammal of any of claims 32-33, wherein the first selectable marker is selected from the group consisting of neomycin phosphotransferase II, xanthine-guanine phosphoribosyltransferase, hygromycin-B-phosphotransferase, chloramphenicol acetyltransferase, and adeninephosphoribosyl transferase.

35. The transgenic, non-human mammal of any of claims 32-34, wherein the first transcriptional promoter element is selected from the group consisting of an inducible promoter, a repressible promoter, and a constitutive promoter.

36. The transgenic, non-human mammal of claim 35, wherein the first transcriptional promoter element is selected from the group consisting of VEGF, VEGFR, and TIE2.

37. The transgenic, non-human mammal of any of claims 32-36, wherein said expression cassette further comprises other control elements.

38. The transgenic, non-human mammal of claim 37, wherein said control elements are selected from the group consisting of transcription enhancer elements, transcription termination signals, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.

39. The transgenic, non-human mammal of any of claims 32-38, wherein said non-human mammal comprises a second single-copy, non-essential gene in its genome, wherein (i) at least a portion of the second single-copy, non-essential gene is replaced by polynucleotide sequences heterologous to the second gene, such that the second gene cannot produce a functional gene product, and (ii) said polynucleotide sequences comprise a second expression cassette which has been introduced into said mammal or an ancestor of said mammal, at an embryonic stage, said first expression cassette comprising

a second selectable marker,

a second transcriptional promoter element heterologous to the second gene, and light-generating protein coding sequences, wherein said light-generating protein coding sequences are operably linked to said second promoter element.

40. The transgenic, non-human mammal of claim 39, wherein the first transcriptional promoter element in the first expression cassette is different from the second transcriptional promoter element in the second expression cassette.

41. The transgenic, non-human mammal of claim 40, wherein the light-generating protein in the first expression cassette can produce a different color of light relative to the light-generating protein in the second expression cassette.

42. The transgenic, non-human mammal of any of claims 32-41, said mammal being a rodent.

43. The transgenic, non-human mammal of 42, said rodent being a mouse.

44. The transgenic, non-human mammal of any of claims 32-43, wherein the sequences encoding the light-generating protein are obtained from either prokaryotic or eukaryotic sources.

45. The transgenic, non-human mammal of claim 44 wherein the light-generating protein is a luciferase.




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B

FIG. 3C-1

3001	AGTCAAAACG	TCTTCACACT	GACACTCTCT	CCTGGCCATG	AAACCCCTGAG	TCTAAGCCCCC	CTTCATGAC	TCTATGGCG	GGATATACAG	TTTTTCAGCC
3101	CAATCTAGGG	CACCTTCGCCA	ACCTTCACCT	CCCTTGGATAC	CCACCAATCC	CTCTCCACAC	CTTAGTCMCC	CAAGAACCC	CATGCCACCA	GGCTGTGAT
3201	GAAGAAAGGC	CTTCAGGTTG	CCATGGCAGG	CTCTCTAGCCC	AGGGCTTGGG	CAAGCTGGG	GGGGAGCTTC	TGATATCTCG	CTTCCTTCG	TAAGAAAAGA
3301	CTTTTTCGGG	GAGTCGGGAC	GGTACCTCCG	GGAGATCCGG	TCCCGGAAAC	GGTCGAGGGG	CCCTCTGAG	ACCTTGAGCC	GACAGGAGCG	ACTTTTTCTT
3401	ACGAGCTGAA	AGAGAGGTTG	CTAGTTCTCT	GGGTTTCTCG	CTTATTTATTG	CTCACTCTCT	GGGGACGCC	CAATGGCTTC	CTCCAAACAC	ACGTCACAGA
3501	TGTTCTGAG	CTGAGGTTG	TCTTCCTCTG	GGGTTTCTCG	CTTATTTATTG	CTCACTCTCT	GGGGACGCC	CAATGGCTTC	CTCCAAACAC	ACGTCACAGA
3601	AAGGCTTCAA	TTCCTTCAAC	CTTCTTCCCA	GGAGAGCTCG	GAAGACAGAA	ACCTGGCCCA	AGACCCAAGT	CAGTAGGTTG	ACGGGAGGAG	GGGATAACAC
3701	TTCCCTTGTG	AAGGGCTTCA	GGGTTTCTCG	CTTCTTCCCA	GGAGAGCTCG	GAAGACAGAA	ACCTGGCCCA	TCTGTTTCA	CTCATCCAG	TGCGGCTGCT
3801	GGTTAGCTAA	GGTGGGGAGG	TGGAAAGAG	CAAGTGGTTG	CAACCTCTGA	GGCAAGTCCCG	TCTAATCTCC	TGAGGCTTAC	TTTGTGAAA	GGGGGACCAT
3901	CGAAAGGAAAT	CGAACCCCTCC	ACCTTCTCTC	GTACAGCAAA	GGTGGGAGCT	GGTGGGAGCT	ACCTGGAGCC	ACTGCGAATG	AAAGGTTATT	GGGGCTGTTA
4001	GGTGGGAGCT	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT
4101	GGGGGGGGGG	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT
4201	GGGGGGGGGG	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT
4301	ATTAAGGAAAT	CTCTCTCTGG	GTAGGATCC	AGGTTTCTCG	CCATCTTCC	AGTCCACAG	CCATCTCTG	AGGGTTTCAC	TAATCCATTG	ATCCTCGGGG
4401	CTACCGATCT	TCAGATAGA	AGAAGGAAAT	AAAGGAGGAG	AAAGGAGGAG	TCAGGAGTTT	TGAAACAGTT	TGAACTCCCG	TGAACTCCCG	TGAACTCCCG
4501	GGGGGGGGGG	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT
4601	GGGGGGGGGG	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT
4701	AGGTGTTGGC	GTGGCTGGG	ACCTGGGCGA	GGCTTGGGCC	TGCTTGGGG	GGGAGGGGGG	TGAAACCTCG	AGGGGGGGGG	TGAAACCTCG	GGGGGGGGGG
4801	CTTCAGGGGG	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT
4901	GGGGGGGGGG	GGGGGGGGGG	TTTGTGCTTC	AAAGGAGGAG	AAAGGAGGAG	TTCTGGGCTC	TTCTGGTCT	CTCTAACTCG	GGGGGGGGGG	CTGGACGCTT

FIG. 3C-2




FIG. 4A

1 GCAACTTCCC AACCGTTGCG CAGTCGGTGT CAAAGTATAT ACCCGTGTCT TACCCGAGGC TAGAACCTTT TAGCCGAGG CGCGCTCCCT AACCGGAGGC
 CGTCGACCG TTTCGACCG CTACCGCCAC GTTTCATATA TGGCCGCCAA ATCGCTTCTG 'ACTCTTGAAA ATCGCTTCTG GCGCGAGGA TTCCGCTTC
 101 TAGGCAAGTA GGCGGAAAGA ANGAAAAGA AATTCGAGA AAAGCTTCA GAAGCTTCA GAAGCTTCA CTTCGTCATA AGGCTGCGA GTCCGCGATC
 ATCCGTTCTAT CCCTTCTCTT TCTTTTTT TTTCAGCTCT CTTCGAGGT CTTCGAGGT CGAGGAGGAA AACGAGTTT TCTTCACCT CAGCGCTCA
 201 ACCCTCCACC CAGCGAGGT TAGGGCGTC AACCGCGTC ACCTCTCC CGCTCTCC CGACGTTAC CGCGGAGGC TCGCTAAACG GTGACGCGCT
 TOGAGGTGGT GTGCTCTCA ATCCCGGAGC TTGGGGCGAG CGCTCTCC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC
 301 CGAACTTCCC GTTCGACCG CGGACCGACG AGCGCGACG CGCTCTCC CGCTCTCC CGCGGAGGC TGAATGGCGA CGAGGTTCTA TTTCGAGGC
 CCTTCAGCG CAGACTCGC CGCTCTCC CGCTCTCC CGCGGAGGC ATTCGAGGT CGAGGAGGAA AACGAGTTT CGCTCTCC CGACGTTAC
 401 GTGGCTTAAAG GAGCGGAGG CGCTCTCC TGATTGGCTG TGCGCGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC
 CGACGAGTC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 501 TTCTTCTT TTCTCTTCTG CGCTCTCC CGCTCTCC CGAGAGCTAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC
 AACGAGAAAC ACCAGAGAC CGCGGAGGC CGAGGAGGT CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 601 TGATGAGGACG TTGCTCTGTC TCAGCTGAA GAGGCTTTCG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 AACAGACAGC ACCAGACAG ATCGCTCTG CTCCGAAACG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 701 AGCTCTCTG GAGCTCTGAA CACTCTGTC TACCGAGGT TTCAAAACACT AGATGAGGAA CGCTACGAG AGCGCGAGG CGCTCTCC CGACGTTAC
 CGACGAGGAA CGTGAAGCTG AGGCTCTAC AACGCTCTAC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 801 CTTCCTTCTG TTCCGAGCT CGTATGGCG AGGGATTCG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAAGGAGTC AACGGCTGCG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 901 CGGGGGGGGG GGGCGTGTG CGGCGCTTCC CGGCGAGCG AGCTCTCTG ACCCGCATCC CGTCAGAGCA GTCTGAGGAA TTCTCTCTG
 CGGGGGGGGG CGGGCGCTCC CGGCGAGCG AGCTCTCTG ACCCGCATCC CGTCAGAGCA GTCTGAGGAA TTCTCTCTG AACGAGGAGGAA
 1001 TCGGCTATCG TTCACTGAAA CCTCTCTTC TCAGCTGGAA GAGACAGACA CTTCGAGGAA ATCGCTCTG CGCTCTCC CGACGTTAC
 CGCGGAGGTC ATGAGCTCTT CGAGCTCTG AGCTGAGCT CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1101 ACTGGAGCTT CGGGCTGGG GAGGCTCTG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC
 TGACCTGAA CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1201 TGTTGGTGGGGG GTTGGGGGGT TTGGGCTGTA TTGGTGTGTT AGTGTGCTG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC
 AACCCACCCCG CAACCCCCCA AACGGACAC ACCAGACAGC TTACAGACAC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1301 CGACCCCCCGG ACACCTTAAAG CGTCACCCG CGGGGGGGG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CGGGGGGGGG TTGGGTTCT CGAGCTCTG AGCTGAGCT CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1401 GTTGAAGAGA ATCTCTCTG AACCTCTG CGTACGGTGTG AGGGAGGT CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CAACTCTCT TAGAGCTGAA TTGGTGACCG AGCTGAGCT CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1501 TGTCCTCTG CACAGGGTGG CGTCCTCTG CGCTCTCTG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 AACAGAGTGA CGTCACCCG CGAGAGAGT AGACAGACAG CGACACACAA CGGGCACCGA AACAGACACA CGAGACAGGA CGACACACAA
 1601 GTTGGAGTGC CGGGCTCTG CGGGAAATCC CGGGCTCTG CGTACCCAGT CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CATCCCTCC CGGGCGAGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1701 CTTCCTCTG CCTATGGCGA GTTGGAGGGG CGAGGAGCT CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAGTGGAGA CGTACGGTGG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1801 GCGTGGAGTGC CTACAGCTG CGGGGGGGG CGGGGGGGG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CGAGCTCTG CGAGTGGAGA CGGGGGGGG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 1901 GCGTGGAGA CGGGGGGGG AGRCAGTAG AGTGGAGCT CGAGGAGGT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CGGGCTCTG CGGGCTCTG CTCTCTCTG ATGAGCTGCG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2001 TCGGCTCAT GAAGCTCTG AACGACACAT AACGGAGGG AGTGTGAGCA CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 ACCGAGCTG CTTCGAGGAA CGTGGTGTG ACCGAGCTG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2101 GAGGGAGCC TGTCGAGCTT ATGGAGGTCG CGCTCTCTG CGAGAGAGT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CTGGCTGCG AGCTGAGCT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2201 ATGTCAGCTT ATTTCTCTG CTTCAGCTG CGAGGAGGT CGTACGGAG CGCTCTCC AGTGTGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 TTCACTCTG TTTAAAGCTG GAGTGGAGA CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2301 TTTCGGGTTG AGAGGGAGG AGTGTGCTG AGGGAGCTG CGAGGAGGT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 AACGGGGGGG TCGAGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2401 AACGGAGGCG GTTGGAGGG AGGGAGCA CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 TTGGCTCTG CGAGCTCTG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2501 CTGGGGGGT CTTCAGGCG CGTACGGAG CGAGGAGCT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAGGAGGAGA GAGCTGGCG AGGGAGCT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2601 CGGGGGGAGA TCGAGCTG CGAGGAGGT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CGGGGGGGGG CGGGGGGGGG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2701 ATGTCACCT CCTGGCTCTG CTTCAGCTG AGGGAGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 TACAGCTGGG GGGGGGGGG AGGGAGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2801 CTGGCTCTG TTTCGGGTTG CGTACGGAG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAGGAGGAGA AACGGAGGAG AGCTGAGCT CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 2901 CCATCTCTG GAGCTGCTG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAGTGGAGGA CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 3001 GCGGGGACCA AGGGAGCTT TTTCGGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 CGGGGGGGGG CGGGGGGGGG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 3101 CTGGGGGGGG CGGGGGGGGG CGAGGAGGT AACGAGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAGGAGGAGA CGGGGGGGGG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 3201 TTCTCTCTG AAAATCTT CCTGGCTGTT TTTCAGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 AACGAGGAGT TTTCAGCTG AACGAGCTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 3301 TGAGCTGTTG TTCTCTCTG CGTACGGAG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 AGTATCTGAA AACGAGGAGA CGGGGGGGGG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 3401 CCTTGTGAGA CGGGGGGGGG TTTCGGGCG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 GAGAATCTGAGT CGGGGGGGGG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC
 3501 CTGGGGGGGG CGTCTCTG AACGAGCTT TTTCGGTGTG CGTACGGAG CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC CGCTCTCC CGACGTTAC CGCGGAGGC

FIG. 4B-1

3601 CAGTTGGGAA GGAGCTTTC AGCCCCCTGG ATCAACAGCA AGAATGTTAT AGTGTTGGGT TGGGGGGGTT AACGCTACTT GTGTTGTTCC TGAACCGAA
 GTCMCCCCC CCTTGACAGG TGCGGGGAACT TGTGTTGGT TCTTACATTC TCACACCCA ACCCCCCCAC TTCAGTGAAGA CACACCCGGG ACTGGGCGTT
 3701 TTCTCCCTTC TGTGTTGCTT AAGCTGGGC CCTGCTGGCA TGTATTTAGA AACTGATGCA CTGAGAAGGG AAAGGAGAGA AGCTGAGTCC GAGAACTGCC
 AACAGGAAAG AGAGAGAGA TACTGGCC CGAGGACCTT AGGTGATCTT TGTGCTGGTC GAACTTCCTC CAACCTCAGC CTCTAGGGC
 3801 AGCTGAAA AGAGAGAGA CGCTGGGAT TTGTGTTGCTT CGCCACAAA CGGGCTGCA AGATCCCCA CGAGAGGGGG CGGGGGGGGG CGGGCTGCC
 TOGAGCTTTT TGTGTTGCTT CGCGGAGCTA AACAGGAGCA CGGGGTTTTT CGGGGAGCTT TCTAGGGCAT CCTTCTCCG CGGGGGGGGG CGGGGAGGG
 3901 CGAGGTGAGA GATTTGGGAG GGTGAGATC CGCTGGAGAA GAGGGGTTGG CGTGGCTGGT CGGGGGGGCT CGACACCCGC CGCTGGGGGG CGGGGGGGGG
 CGTCCAGGCTT CTGAGGAGGCG CGGGGGGGGG CGAGGAGCA CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4001 CGAGGAGAC CGGGGGGGCT GAGGGGTTGGT CTGTTTACAC ACAGGAGAAT TCAAGTGGTCC CGGGGGGGCT TGGGGGGGGT TGGGGGGGGT TACAGTGGGG
 CGTCTGGGGG CGGGGGGGGG CGGGGGGGGG CGAGGAGAGA TGTGAGGAGA AGGTGAGGGG GAGAGGGGGG GAGGGAGGGT CGGGGGGGGG CGGGGGGGGG
 4101 CGGGGGGGCT CGGGGGGGCT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4201 TGCTGTTGAA AGCTGTTGAGA CAAACAAAC AACAAACCCG CGAGGAGCA AGAGGGAGGA AGATGAGGGG GAGAGGGGGG GAGGGAGGGT CGGGGGGGGG
 AGAGGAGGTT TGTGAGGAGT TTGTGTTGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4301 GTGGGGGGCC TTGTGACTTC CTGTTGAGG ACCTGGGGGG CGTGGGATGG GAGATGAGGG AAGGGGGCTT TTGTGTTGGT GTGGGGGGGG CGGGGGGGGG
 CGACACTGGG AAAGTGGAGA CGAGGAGCTG TGAGGAGGGG AGAGGAGCTG CTGAGGAGT TTGTGAGGGGG CGGGGGGGGG CGGGGGGGGG
 4401 TGCTGGGGGG CGAGGAGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4501 ACTCTGGGG ATAGAGAGCT GAGTGGGGGG GTGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 TGAGGAGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4601 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4701 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4801 GAGGAGATGA CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 4901 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5001 TGTGTTGCTA TGTGTTGCTG AGCTGTTGAGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 AGAGGAGGAGT AGAGGAGGAGT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5101 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5201 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5301 TTGTGTTGAGT AAGCTGTTG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5401 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5501 ATGGGAGCTC ATGGGAGCTC TTGAGGAGG AACAGGAGGTT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 TAGGGAGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5601 ATGGGAGGG AGAGGAGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5701 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5801 GTGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 5901 TTGTGTTGAGT TTGTGTTGAGT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6001 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6101 GTGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6201 TGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6301 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6401 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6501 AGGGGAGCTG TTGTGTTGAGT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6601 TTGTGTTGAGT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6701 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6801 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 6901 ATGGGAGGTT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 7001 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 7101 TTGTGTTGAGT CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG
 CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG CGGGGGGGGG

FIG. 4B-2

7281 CTGCGTTTCC CCAATTGTCG TCTTACTATCA CCTTGTGTCTC CATTAGTGT GTGTCCTAAGG GCGACCCCGC TGAGGACTCC TTGGAGAGCC AGCTTCGATG
 GACCCAAAGG GGTAGAGGCG AGAGAGCATG CGAACAGAGG GTTAATCACCA CACAGAGTC CGTGCGGCAG AGCTCTGGC AACACTCTGC TGAAGAGATC
 7381 CTGAGGTTCA TGAAGAACAG AATGCTCTG TCGGCTGTC TCTGCTCTG CTCAGTTTCC TCAAGAGCC AGGCTCTAGG GTGAGTACAG AGCTCTGGC
 GAGCTCACT ATTTTCTG TTDAGCGCC AGCGACAGAG AGAGGTGAGC GAGTCAGATG AGTTTCTG TCCGGATTC CAGACTGAG TGAGGATG
 7481 CCATTCTG TGCAACCGAG AGACAGCTG GCGGGGGAGT GAGAGAGAG AGAAGAGAG AGAAGAGAG AGAAGAGAG AGAAGAGAG AGAAGAGAG
 GGTAGAGGCG AGTTTCTG TCTGCTGAG CTGGCTCTG CTGTTTACT GTGTTTACT GAGTCAGAG TTAATCTG TTAATCTG
 7581 GACTGGATGA GCAAAAGCTT TAAAGGAGAG CAGGAGAGTC CTGAGTTTT GGAGACTTAT TAAATCTG TCTGAGTGA CTTGGAGTGA GAAAGCTG
 CTGAGCTACT GGTGGCTCA ATTCTCTCT GTGCTCTGAG GAGCTTAAAGA CCTCTGAGTA ATTTAGGTA GAAAGCTGAG GAGAGAGGAG
 7681 GGAGGAAAAA AAGTGTAAAT ATGAGAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG
 CCTGGAGGAG TTCAGAGAG TAACTCTG TTTTCTGAG TTAATCTGAG CGAGAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG
 7781 TTGAGGGAG CAAAGCTGAG TAGAGCTCC CGGGGAGAG GTGGAGAGAG ACCAGCTCTG CCTAAACAG CGAGAGGTTG GAGGCTGAGA CGGGAGGAG
 AACGCTCTG GTTTCAGCT AGCTCTGAG CGGGGCTTC CACCTCTGAG TGTTGAGAGA CGGATTGAGC GAGGCTGAGA CGGGAGGAG
 7881 CTGAGGATCA TCGGGGGAG AGGGCTCTG TCTGCTCTG TAAATCTGAG CGAGAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG
 GACTCTGAG AGGGCTCTG TCGGGGGAG AGGGCTCTG AGGGCTCTG AGGGCTCTG AGGGCTCTG AGGGCTCTG AGGGCTCTG
 7981 AGATGAAAGA TTTCTGAGT TTGAGAGAG TTTCTGAGT TTGAGAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG
 TCTTCTGAGT AAAGTCTGAG AAAAAAGAGA AGAAAGAGAG AGAAAGAGAG AGAAAGAGAG AGAAAGAGAG AGAAAGAGAG AGAAAGAGAG
 8081 AGAGTGTAG AGTCAGTTCC ATGGGGCTCTG GAGTTTGGG AGAGGGGGC TAAAGGCTCTG GTGCTCTGAG ATTTAGGAGA AGAGGCTCTG
 TTTCTGAGTC GAAAGCTGAG TACGGGGAG CGGGGGCTCTG ATTTAGGAGA AGAGGCTCTG TAAAGGAGA AGAGGCTCTG
 8181 GTGAGTTTCA TTTTCTGAGT TTGAGAGAG TTTCTGAGT TTGAGAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG AGAAAGAG
 AGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG
 8281 GAAGCAGAG TTTCGAGGG TCTGAGGAG CGGGGGGGAG GAGGGAGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CTGCTCTG AGGGGGGGAG AGGGGGGGAG CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8381 AGGTGATGGA GTTGGAGAGC AACTCTGAGT GAGTTTGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 TCTGCTCTG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8481 TGGTAAATAC CACAGGGAG TCTGAGAGAG CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGCTTATTCG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8581 TTGAGGGAG TGGCTCTGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8681 GATGCTCTG GTGCTCTGAG CGGGGGGGAG TTGAGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CGAGGAGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8781 GGTGTTCTG TTTCAGAGAG GATAATGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8881 TATGCTGAGT TATGCTGAGT TATGCTGAGT TATGCTGAGT TATGCTGAGT TATGCTGAGT TATGCTGAGT TATGCTGAGT
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 8981 AGGGGGGGAG GAGCTTGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 TCTGAGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9081 AGAAGACAGA AATTCAGAGT TCTTCTGAGT AGTTCTGAGA AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 TCTTCTGAGT TTGAGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9181 TTGAGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9281 CATCCCCTTC TCAAAATCCA CTGAGCTGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 GTGAGGAGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9381 CACCAATTCG TTGAGGAGAG CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 GTGAGGAGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9481 GACACAGAGT TCTGAGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9581 TATTTCTGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9681 GTGAGGAGAG CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9781 CCTCTCTGGAG CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9881 GGTTGGCTGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 9981 GTGGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10081 TAATCTGAGT ACATTAACCA GAGAGAGGG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10181 GTAGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10281 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10381 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 TCTAATCTGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10481 GGTGTTGAGTA GTGAGGAGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10581 CAAGGAGAGA GAGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 GTGAGGAGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10681 TGGAGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG
 10781 CGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG AGGGGGGGAG

FIG. 4B-3

10801 GCTCGAAA AAAAGAGA GAGGCGAG TGGAGGCA AGAACTTA CATTCTTG GTTGCTTC CGTGTGCG
CAGACGTTT TTTCATCTCT CTCTCCCTAC ACTCTGCGCT TATTCGAACT GAAAGAGAC GACAGAGAC GACATCAGAT AGACGCTTC GTTAGGACCG
10901 TTGCTCCAA GGTGGAGGT AACATTCCTT TGGAAAGGT ATTCTCTCG CTTTATTTT CAGTTTTTTT TATGAGGCA AGGATGGAC CCAGGACCC
AACGGGGTTT CCACTCTCA TGGTAAAGA AATTTTCCA TAAAGAGAC GAATGAAAGA AACGAAAGA AACGACACAC TCTTACCTG GGTGCTGGGA
11001 TGGCAACCAA GGTGAGCTT TACCCACTCA GGCACGCTCG AGCCCTCGC TGGGGGTTG TAGGCAAGG TTCTCCACCT GACCCACACT CCCACACCCC
ACCCCTTTT CCAGACACA AATGGTACCT CGGTGAGG TGGGACGTC ACCCCCTAG AGCCCTCGC AGAGTGCTGA CGCGCTGAGA GGGGTGGGG
11101 ATCCCTCTCT CGGAGAGCTT AGCCAGTCC AGCCCTAGCC TTTCATCTTT TAAGACGTC TTAATGAGC TCACTT
TAGGAGAGA CCTTCAGA TCCCTCAAGG TTTGGGATGG AAGCTAGAAA ATTCCTGCCAG AGTGATCTCG AGTCGA

FIG. 4B-4




FIG. 5A




FIG. 5B

VEGF project	VEGFR2 project	Tie2 project
Screening primers	Screening primers	Screening primers
Primers: VF1-VR1A Product size: 0.69Kb	Primers: KF1-KR1 Product size: 0.45Kb	Primers: TF3-TR1 Product size: 0.45Kb
PCR program	PCR program	PCR program
Hot start	Hot start	Hot start
94°C 40 sec 65°C 1 min 30 sec 72°C 1 min 30 sec	94°C 40 sec 58°C 1 min 30 sec 72°C 1 min 30 sec	94°C 40 sec 58°C 1 min 30 sec 72°C 1 min 30 sec
40 cycles	40 cycles	40 cycles
Confirmation primers	Confirmation primers	Confirmation primers
Primers: VF2-VR2 Product size: 0.98Kb	Primers: KF2-KR2 Product size: 0.58Kb	Primers: TF2-TR1 Product size: 0.47Kb
PCR program	PCR program	PCR program
Hot start	Hot start	Hot start
94°C 40 sec 65°C 1 min 30 sec 72°C 1 min 30 sec	94°C 40 sec 65°C 1 min 30 sec 72°C 1 min 30 sec	94°C 40 sec 58°C 1 min 30 sec 72°C 1 min 30 sec
40 cycles	40 cycles	40 cycles

FIG. 6




FIG.7




FIG.8




FIG.9




FIG. 10

SEQUENCE LISTING

<110> XENOMON CORPORATION

<120> TARGETING CONSTRUCTS AND TRANSGENIC ANIMALS PRODUCED
THEREWITH

<130> PXE-008.PC

<140>

<141> 1999-12-16

<150> 60/152,522

<151> 1999-09-03

<160> 39

<170> PatentIn Ver. 2.0

<210> 1

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer PGKF

<400> 1

atcgaattct accgggttagg ggaggcgctt t

31

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer PGKR

<400> 2

ggctgcaggt cgaaaggccc ggagatgagg

30

<210> 3

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer NeoF

<400> 3

acctgcagcc aatatggat cggccattga ac

32

<210> 4

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer NeoR

<400> 4

ggatccgcgg ccgccccca g ctggttcttt ccgcctc

37

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer TKF

<400> 5
ggatccctcta gagtcgagca gtgtggttt 30

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer TKR

<400> 6
gagctcccggt agtcagggtt agttcgtccg 30

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer F5R51

<400> 7
gtacattnaa atcctgcagg 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer F5R52

<400> 8
agtcctgca ggatttaaat 20

<210> 9
<211> 77
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer F3R31

<400> 9
ggcccggtt taattaatgc atcatatggt accgtttaaa cgccggccgca agcttgtcga 60
77
cgccgcgcggc gcccggcc

<210> 10
<211> 77
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer F3R32

<400> 10

gateggccgg ccggcgccgc gtcgacaaggc ttgcggccgc gtttaaacgg taccatatga 60
tgcatattaatt aagccccg 77

<210> 11

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer VN1R

<400> 11

ctgtatTTAA atctgcccac cctattcagg acagtagtc 39

<210> 12

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer VN1F

<400> 12

ccaaatgcata aacccagcca ggaggagtgc g 31

<210> 13

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer VN2R

<400> 13

aacgcgtcga cttcggagat gtttccccca taaccagg 38

<210> 14

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer VN2F

<400> 14

ttggcgccgc ccatagagaa gagacaccaa aggcacgctc 40

<210> 15

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer FosBlF

<400> 15

ctgtatTTAA atcccgTTTC tcactgtgcc tgtgtc 36

<210> 16
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer FosB1R

<400> 16
gtctcctgca ggcttcctcc tccttggccc ttgcg

35

<210> 17
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer FosB2F

<400> 17
aacgcgtcga cggatggat tgaccccccag ccctc

35

<210> 18
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer FosB2R

<400> 18
ttggcgcc ccttgccccc acctctcaaa tgc

33

<210> 19
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer VF1

<400> 19
acctcactct cctgtctccc ctgattcccc a

31

<210> 20
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer VR1A

<400> 20
gctctggcgg tcaccccaa aagca

25

<210> 21
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer VF2

<400> 21
cccttccaa gaccgtgcc atttgage 28

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer VR2

<400> 22
actttggccc tgtcccttc tctgttcgc 29

<210> 23
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer KF1

<400> 23
gctgcgtcca gatttgcct cagatgcg 28

<210> 24
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer KR1

<400> 24
ttctcaggca cagactcctt ctccgtccct 30

<210> 25
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer KF2

<400> 25
cagatggacg agaaaacagt agaggcgttg gc 32

<210> 26
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer KR2

<400> 26
gaggactcag ggcagaaaaga gagcg 25

<210> 27
<211> 29
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer TF3

<400> 27

agcttagcct gcaagggtgg tcctcatcg

29

<210> 28

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer TF2

<400> 28

caaattgcacc ccagagaaca gcttagcctg c

31

<210> 29

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer TR1

<400> 29

gctttcaaca actcacaact ttgcgacttc ccg

33

<210> 30

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer F51

<400> 30

cccaagtgtct ctgattttagg gagagcacct gag

33

<210> 31

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer R51

<400> 31

ccagactgcc ttggaaaaag cgccctc

26

<210> 32

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer F52

<400> 32

cagtgagagt cttctctgtc cctcaatcgg ttcttg

35

<210> 33
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer R52

<400> 33
tggatgtgga atgtgtgcga ggccag 26

<210> 34
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer F31

<400> 34
aatcaaagag gcgaaactgtg ttgtgagaggt cc 32

<210> 35
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer R31

<400> 35
cggtccccca aaatgtggaa gcaagc 26

<210> 36
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer F32

<400> 36
gaatccatct tgctccaaca ccccaacatc 30

<210> 37
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer R32

<400> 37
cgccctcctct ccccaagtctc cccttg 26

<210> 38
<211> 4998
<212> DNA
<213> Mus sp.

<400> 38

tccacccacc tgggtctcac gtcggccgccc ttccatgtta acttcatggt taaagaagcc 60
tcacccgggg agggtgtggt gccacagaag gaagggtgt cccacaagcc cccagtgtct 120
ctgatttagg gagagcaact gagcccaact agagtctct ctgtccctca atcggttctg 180
aaattccccca cttgcctcc ttatccaggc gacagggtg cccaccctat tcaggacagt 240
agtctaaac tcgttagccaa cagactttt attgggtctgg gagaagaga tgaggctct 300
gaagctcagc cgagtgggt ctgatccata cttctcagag gtccggcagc ccagccaata 360
ctgagcaatg gagcgtgggt aggaggatt cacagatcc actcgccggg ttctaagggt 420
gactcggtag tatttgtctg aaagaaagaa tggaaaaagg gttatgttag attctgcctg 480
atccgttcca ctggtcccaa gaaggataaa ggcttttct cagaaggaa agtgaacatc 540
cacaaggcag ataatgtcac catctacagg ctgtgttcag caccaggaa ccaagacctg 600
caggcaaggc cttagccaaa ccagtctaag gtagtagaaag gggctccac ctccagagaa 660
gaaatagacg ctctgaatgg gctcgcagg ggcaggatca agccagtcca tatcataatc 720
atagttgttg taggttctca gcccactctc ctgcgtggag aacaagaga accagattga 780
acgtgtatgaa cgacgggagt tcgagctctg gtcgcgtctg tggccacgccc ctggcgtga 840
acgatagegc ttccggcttc tacgcttaga cttctgttt ttggcttggg cagagtggg 900
taaggagcca gtgacgtaga tgccggccggc catagcagcg tccactttcc ctggcacacc 960
atgccagttc cggctgtatg attgggttc tctggctcca tctgttaacag ggaagggtt 1020
aatgcacttg gcagattctg gctttagttt ctccagcaag gttgtctgtc tatctattta 1080
tctatctta tctatgtatc tatctatata tctatgtatc tatctatcta tcatctac 1140
acctacttac ctatctatgt atctatctat ctatcatcta cctacatct tacctatcta 1200
cctatattt tgggttttgg tttctttga aacaggatct tagcacctac ctatggctgg 1260
tttgcactc actatgaagc cataactggc ctcttaactc acaaagatcc acttgcctgt 1320
gtctctgagt gctgggatta aaagcatgtg ccactacacc cagctccagt aggacctta 1380
gaacacattt gctatgcctt gcctaagaca cacaactcag tcccccaggcc ccagccctccc 1440
tgtcttagagc ttttccat cctctctcca ctgtatccct tgaatctctg ccccatccga 1500
aacccctcag cgccgagccc ctccctctgc tgggttaggc aaagtccaaag gtatggatc 1560
caaataagacg caagccatcat cccccaaaag tcaacagaag caaagtctag ccagagaaaa 1620
cagctttga tcgatgggt cacagttcca ggccccccc ctggaaagccc ccactatcac 1680
agcccaagttt ccagagaaag aagccagcct tgctctccct ccataccaga ggtatctgccc 1740
cagaagagga gttcggaaat gttctccag ctgtcccgct gaagcaaggc aaagtgtca 1800
aacacggctg acagagagct gccttcgcac tcctcttgc tgggttgc tggaaattcg 1860
tactcccaagt actgcttccc tgaggagcag aacagctggc atcaggagag atctgacc 1920
ggcagagagg aatcatggaa tagaacaggg actccaccac ctgccccctt ctctccacc 1980
ctgagtagcc ttgaagaagt agaccccttc cggccactg taacgggtggg caggaaggc 2040
gaacgctgca tcaacattgt ctggatgtcc actgaagcct tcggagatgt ttcgggata 2100
accagggtcc aggacccat cctcaaagcg ccagactga ctaccctgaa agacagagat 2160
cagaagggtg aggacatacc gtcggccaca gaagcgtcc tatatcctaa actggctgtc 2220
acctgctctt ggagtccctg actgcttgc ttccacagct cccagcacg tccatggcac 2280
ccttacctt gcctcagact taggtctggt accttgaaca agtaggtctt cccctgacag 2340
ttgatgcgag tgaaggcagc atcgatgggg ccctcaatgc cccagacatc ttggataagt 2400
ttgggttacc caggcctcact tgccgtctca tctagctcat agcgtactg ccctagaaca 2460
ggggaaactg tgtgagaagc agatgagcct aaggcagatc cgaccggccac cagacctgtc 2520
catagagtca cctcggaaagg caaagagggg cccattctt agatccgtga aggcgtcaaa 2580
ggccttcca ctgcacagtt ctccctctgg aaactcaggg gtcccttgat cagtgggtgc 2640
ggccctttagg atctccctt gttgtccac tttagggcgt ggggtgttt gctgttctc 2700
aggatctagg aaggctgtcg gctttagagt gccgtccgtc cgaggattta ggtcacccggg 2760
tggagaggtg ttctcgggtt gcacaccggg gttggatattt ttcttgggtt cctccacgt 2820
gtcatagctc caataatcat cctctggcat agtgaacacg tccccccggc ttactgcagg 2880
cagaacgggg agcagtgtgt gtcaggctgt ggagggagcc ccaggcccac ccaccaggc 2940
tctgaactca ccttgggtt tgactgtcc catgtatcg gcacagcagc tctgatagta 3000
agtgc当地 gtcgtccact gacacttctt gctggccatg aaaccctgag tgcagccggcc 3060
cttgcatgac tctatgggg ggaatatcg gtttacagcc caatcttaggg cacctgccc 3120
actgcactt cccttaggtac ccaccaatcc cctccacac ctgggtcagc cagagaaacc 3180
catgccacca gggcttagtat gaaaaaggcc ctcagggtg ccatggcagg cctctagccc 3240
agggccttgg caagctggc gcccggcttc tggaaatctcg ctgtccctgccc tgaaaaaaga 3300
agcagactga agaagagttt ctatccctt gggtttctgc cctttatattt ctcatccct 3360
ggcccttggcc cattgcctc ctccaaacac agtgcagca aagggtcaca ttcccagaac 3420
cccagccca ggagagctgg gaaacagaaaa accctcgcca agaccaaagt cagtagggc 3480
acggggcggg gggataaacac gcttagctt gctggggagg tggaaagaag catgtgttgc 3540
caccctctga gcccgtccctt taatctccc tgagcattac tttttataaa gtgggaccat 3600
ggtgccctgc ctcatcaggt gttgagagat tccgtgagct agaacagaca aaacgtttcg 3660
tgccctggagt agcttccaac tcattccat aagccgttat cgatttactg tttgatcagg 3720

ctagggtgctt	gtcccatcct	accggccgtt	tgcgtatctgg	atttttgggg	caagaagggg	3780
ggttggggga	gagctggcaa	gcactttggg	ggagggtttc	ttttcttctc	ataaaagaac	3840
aaagcttcat	ttctggcctc	tccttggct	ctctaagctg	ggtgttacag	cataggaaat	3900
agtgggtcag	agtctattct	tctttcttta	tttttttag	atttatttat	tttatgtttt	3960
gtgtataagt	gtctgctcac	atgtgcacat	gtgcaccaca	tgcatgtctt	gtgtctatgg	4020
aggtcagaag	agggtttga	ataccctgga	actggagtt	tgaacagttt	tgagctgccc	4080
tgtggatgct	gagaatcaa	cccaggtcct	ctgttggaaac	aagtactctt	aaaggctgag	4140
ccatcttcc	agtcccagag	cccattcctg	aggcttcac	taatccattt	atccctgggg	4200
gaccacctg	gccacacctt	caatgacctc	atttattttt	aaaaaaaaat'	ggactcattt	4260
ggcatacttt	ctagactcac	atactaagt	ggatttctct	ataaaagaat	gctcaactggg	4320
gttagatgtcc	agggtttggg	ccaaatttcca	agcaactggca	cacttctgaa	gccccctccgt	4380
tttctgttct	gtaatcacag	gcgagcgtgc	cttgggtgtc	tcttcttat	ggacccgca	4440
agtctcagcg	gcaaaatgaa	acactaaatt	ttactcccta	cagacgcgtt	aaggcttaat	4500
ggaaaaccggc	attaaagggc	tttaagaatc	tcaactgcga	ttctttaacc	atccggaggg	4560
gacgtggata	catgttagcca	gcttgcttcc	acatttttggg	gagccgagcg	agcggttagga	4620
aatggaaagac	agctctttac	agccctttct	acagcatctt	gcacaccacc	aaggggagac	4680
tggggagagg	aggcggagcc	agggtggggc	gtggctggag	acctggggta	ggcttgcgcc	4740
tgcgtcgccc	gcccggcccg	tggaaacctag	aggcggggcg	tcaaattctt	gactctgtt	4800
ctcagaggcg	tgggtgttgt	tgagcatctt	agctccgtt	tgttttagatt	ggagcagcgc	4860
tttggcccg	gcacccggcgt	ctctaccctc	ccgggtctgg	tccatgttcc	tctctccctt	4920
catgcccccc	ctaaatgtcgct	gagttccggaa	gctggccctcc	tccttctgtt	tctacacttg	4980
tagccccagca	ccttttacc					4998

<210> 39
<211> 11176
<212> DNA
<213> Mus sp.

<400> 39
 gcagctgggc aaacgttggc gatgccggtg caaagtatat accccggtgg tagcagaagc 60
 tgagaacttt tagccgaaaag ccggotccct aagccgaagc taggcaagta ggggaagaaa 120
 aaaaaaaaaa aaattccaga gaagcttcca gagcctcctc ctcttcctc ttccctcaaa 180
 aggactgcaa gtccgcagtc accctccacc cagcaagagt tagggcctcg aaccccggtc 240
 acgctgcctc cgctcctgc cgaacgtAAC gggggaccgg tgcgtaaAGC gtgacgcgt 300
 ggaatccccc gtctgacgCG gggcacgcAC agggcgcAGC ccctccgccc gccccgcccc 360
 tgacgtccgg gcacgttcta ttttggAACG ccgaggccAC gttgctaagg gagggggcag 420
 cgtggctttg tgattggctg tcgcgcgcAG ctttagccAA tcagcgttcc ctccctatt 480
 gtagagcgtA gctcccttcC ttgcttttTG tggcttctCC cgtgctgggg gtctccaaga 540
 ggagagctAG gattcttGTC gogatcgGGA ctctgttGCA ccccatggTC tgcgaggact 600
 tgtgtggacc tggctgttG TGATAAGCTA gaggctttG gctgagtgTT agcgcctcta 660
 agggggAAact gaaggcctca tccttctcAG gcacacataT acgtgctcCT gagctctaga 720
 cactcagtcc ttccgaggGT ttcaaaACACT agatgagcTA gcctacggAG aggcagccAG 780
 gtggctctA aaaggctctGC ctccccttAG ttcccaggGT ctgattggCC agggattcAG 840
 cccttcctc gccacgcccc cttagatgtAG taagcctcta ggattccact tgccggaaagg 900
 gggggggggg gggcgtgtAG gacgcttCTT ggggacgcAG atcctatgtc accccatccc 960
 ctgcaagaca gtctgagaga ttctcgctGT cactttctc tgcctatcAG ttcaactgaaa 1020
 cctgtcagtc tcaactggAA gagacagACA ctctggaaaggG atgctctCAA ctcttagGCC 1080
 ggtcccccaa caccgttGA actggatCTT ccgcctcgGG gagccctcat gcagtggggg 1140
 gtgtgtttgt gtgtgagtGG agaggaaggC ttggcttAAGG cctctccctc tccctccctc 1200
 tgtggggggg gttggggggG tttggctgtA tgggtgtgtG aatgtctgtG gctccatccc 1260
 gggagttgt caccaggTT TGTCCAGCCT CCTCTCCAC ccaccccccc acacctaaga 1320
 gtcaccaacc cgggggtgtGA ttcaacccACG tgcaacctt ccccgaggAA 1380
 gaaggaggag gttagaaggCA gttgaacAGA atctctcATT aaccactgcG tcacgggtGA 1440
 gtggaaaggGT ggggtgtgtG gtttttGcc tggacacacAC acatccacAC ccgctcacCC 1500
 tgtgctcaCT cacagggtcG gtctcttCA tctctcttGG gctgtgtgtGT 1560
 ttgtttgtgt gtctacgcCT gtgtgtgtAT gtctcacCCC gtaggagtgc gccggctcg 1620
 gggaaatGCC cggctccCTC gtgccaacGG tcacccGAAT cacaaccAGC caggatctC 1680
 agtggctcgt gcaacccACC ctcatcttCA tcatggccCA gttccaggGG cagccactGG 1740
 cctcccaGCC tccagctgtT gacccttatG acatGCCAGG aaccagctAC tcaaccccAG 1800
 gcctgagtgc ctacagcactGGCAGGGCAA gggaaagtGG tgccgttca accagcacaA 1860
 ccaccagtgg acctgtgtCT GCGGTCCAG ccagagccAG gcctagaAGA ccccgagaAG 1920
 agacagtaag tatgaggcCT caggaggTGG gatggaggAG cctagctagg gatgtgggct 1980

cagtttgtac agtgccttc tgccatgcataa gaagatccct agcacagcat aagccaggag 2040
 tggtatgca gacgttaac cccagcttc agaagggtga ggcaggagga gcaggagttc 2100
 gagggcagcc tggctactt atggagtcca gcctgcactg caagagatca ttatttcaa 2160
 aagttggct tgggggagg tgggtgaggg aagtaagaga aagtgcacgt aattttgtca 2220
 cttaatagtt ggagggtctt ctgaggcctc aagtctgaag gaactttacc attctggcca 2280
 gtgaggagta ggggttatta tttgggttc aggaggaagg aagtttctt agggctgata 2340
 gaggtacccc cagatctcat ggtccttatac tctgactcag cttaccccg aagaagaaga 2400
 aaagcgaagg gttcgcagag agcggaaaca gctggctca gctaagtgc ggaaccgtcg 2460
 gagggagctg acagatcgac ttcaaggcggt aaggaggagt ctgggggtgt cttgaggccg 2520
 tgcggggagc actctgcctt gtttcccccc cgtttctcac tgcctgtg tcctaaacga 2580
 ggaaacccccc tcttagggaa caggggtcag tataaggctga tggagtggct ccatatgcata 2640
 gctcagaccc atgcccactt acttcgact gttcccaact ttccctgaat atgtccccac 2700
 atgtcaccctt cctggcttc tctcagccta aggagacaag cttagaggagg taattcttc 2760
 accttttttt cttcaactaaa taataatcca ttttgcottc ctgcctccat tttttttcc 2820
 tgagctgggg atctacccgt cgtagttcag ccctcctccc ccaacttgat agcctcaagt 2880
 ttcagccctt ggctgagatg ccatcatctt gactggctt ggctggaaac tattttgtgc 2940
 taagtcaatt cttgtctgc tacattcagttt atctacagty ctggcgaact tgagctgtg 3000
 gogccacca agcccaccc tttctctttt ttttacccca gtgcacccccc ccacacacaa 3060
 aacttcatgc ctgccccctt aaccagggt ggcgtctcga ctccccgtcg ggaggctgaa 3120
 ggagatgggt aacagaacctt cattaaaaac aacacataag cattacccatc tgactcaaca 3180
 aactgttagt ttttctttt ttccctctcaa aaaattttt cgtttggta ttttattttt 3240
 gcttatgtt gagttagtgc tggtagccca cagcacacat acgaggctcag agggaaattt 3300
 tcatagtttt ttctctctt ccgtgttgc ggtgttgc ggcatactcc ttcaactcagt 3360
 gagctacaat gccccctt gccccttaag gcagagactt ccttagtaca gggggaccct 3420
 ttccctggcc tctcaaagttt gagattacaa atgttccacca tcacaccagg ctggagttc 3480
 ttgcctatca gtgaetccca ctccctgccta gtttctccc aaccatctt tagtctgtat 3540
 gggaaaccga ggcacgagta gcatggctca ccaggatttcc ctcttagggg acggccccc 3600
 cagttggggag ggagctgtcc agccccctgg atcagcagca agaatgtatg agtgtgggg 3660
 tggcggggtg aagctactctt gtgtggctc tgaccagcaa ttccctttc tctgtctcc 3720
 atgacctggc cctgtggga tccattagga aactgtatcag ctggaaaggagg aaaaggcaga 3780
 gctggagtcg gagatcgccg agtcacaaa agagaaggaa cgcctggagt ttgtctgg 3840
 ggcacccacaaa ccgggtctgca agatccccca cgaagagggg ccggggccag gcccgtggc 3900
 cgaggtgaga gatttgcaccc ggtcaacatc cgctaaaggaa gacggcttcg gctggctgct 3960
 gccgccccctt ccaccaccgc ccctggccctt ccagagcage cgagacgcac ccccaaccc 4020
 gacggcttctt ctcttacac acagtgaagt tcaagtccctt ggcgaccctt tccccgtt 4080
 tagcccttcg tacacttcctt cgtttgttcc cacctggccg gaggcttcg cgttccgg 4140
 cgcacccacgc accagccgca gcgagcagcc gtccgaccctt ctgaactcgc cttccctt 4200
 tgctctgtaa actctttaga caaacaaaaac aaacaaaaacc gcaaggaaaca aggaggagga 4260
 agatgaggag gagagggggag gaagcagtc ggggggtgtgt gtgtggaccc tttgacttt 4320
 ctgtctgacc acctggccccc tctgccatcg gacatgacgg aaggacccctt tttgttttt 4380
 gtgtctgtc tctggttttc tggccccgg cgagaccgg gagctggta ctttggggac 4440
 aggggggtggg gccccccatgca acaccctcc tgcatacttt tgcctgtta cttcaacccca 4500
 acttctgggg atagatggct gactgggtgg gttaggggtgg gtgcacaccc cacccttggc 4560
 gtcttacgtg aggctggagg gaaaagagtg ctgagttgtgg ggtgcagggt ggttggaggt 4620
 cgagctggca tgcacccatc gagagacccca acgagaaat gacagcaccgc tccctgtt 4680
 cttttcccccc acccaccctt ccaccctcaaa ggggtcaggg tgaccaagat agctctgtt 4740
 tgctccctcg ggccttagct gattaactta acatttccaa gaggttacaa cctccctctg 4800
 gacgaattga gccccccactt gaggaaagtc gatccccctt tggggagtct gctaacccca 4860
 ctccctcgatc attccaaaat gtgaacccctt atctgacttc tcaacttcc cctctggga 4920
 aaactggctc aggttggatt ttttcttcg tctgctacag agccccctcc caactcaggc 4980
 cogctccac ccctgtcag tattatgtca tgccttcctt acctcaacc ccaccctcagg 5040
 cgcccttggc cgtccctcgatc gggccttactt ggtttgggc agcaggggggc gctgcacgc 5100
 ccacccatccgatc ggagccgtttt atactgtgaa tgagtggctc gattgtgggg cgcggccggat 5160
 gggattgacc cccagccctc caaaaactttt cctggccctc cccttcttcc acttgcctcc 5220
 tccctccctt tgacagggag ttagactcga aaggatgacc acgacgcata cccgtggcc 5280
 ttttgcgttgc gccccccactt ttttctttt aagtccttcg cttccctccag ccttaggacgc 5340
 caacttctcc cccacccctgg agccccccat cctctcacag agtgcagggc aattttcaga 5400
 gaagtttca gggctggggc ttggctccc ctatctcga tatttgaatc cccaaatagt 5460
 ttttggacta gcatacttaa gaggggggctg agtcccactt atcccactcc atccaattcc 5520
 ttcagtcaccatc aagacgagtt ctgtcccttc cctccagtt tcaactcgtg agaatccac 5580
 gagtcagatt tctatccatc aatattgggg agatggccc taccggccgt ccccccgtgct 5640
 gcatggaaaca ttccatccatc tgcctgggc cctagggttcc aacactaattc cccaaacccca 5700

tgtggttctc ctcattccta gtgctggac cctttaatac atttcctcat gttgtggta 9480
ccccaccacc accataaaat tatttcatt gataacttcat aactgttaatt ttttctattg 9540
ttatgaatag taatgttaagc atttgtgtt cccagtgtac ttagatgacc ctgtggaaaga 9600
gtcattccac cccaaagggg tccccaccac aagtttaagaa ttctgcctat agaggaatca 9660
cagggaccat ggattaacac ttgggtcgac ttttgggtcg ccttctggga ggcgttagag 9720
ctaatacgac agttaacat ttctgaaatt ttgtgtgtgt gtgtgtgtgt gtgtgtgtgt 9780
gtgtgtgtgt gcccgtggc ggggtgttagt ataggccagt ggctttagtgg ttcctggacc 9840
cattactcac cagaactctc ccctcacatc attctttgtat gtgaacacta tgtcttcata 9900
gtggcgggtgg caatagcagc aacagtgaac taaattttaa aagtagaact cagctggaga 9960
tacaatattt gcaatgttga agttgggtgt gattgtctaa taacttaata acataaccca 10020
gaagagagggc cccttggtct tgcaaacttt atatgcctca gtacaggggg acgccaggcc 10080
caagaagtgg gagtgggtgg gtaggggagc agggtggggg gagggtatag gggacttcc 10140
ggatagcatt tgaaatgtaa atgaagaaaa tatctaataa aaatttgaaa aaaaatgtta 10200
ccccagtttgc gcctggatct cactacotca accagactgg catgtgactc tgctgagatc 10260
tgctacttc tgcctcctgg gtgcagaaga caattttgg aagtttagtgc tcttccttca 10320
tcttggat tccagggtt gaactcgggt catcagggtt ggctgcaagt gacttactta 10380
ggtgtctccc agaccctctc ggtttgattt gtttagatgt gcacttcatg cctgacttcc 10440
gcactatgtt gatagagcaa tgcctataac atctcctaca atgatatgtt tatcaagagc 10500
caagtgtat gatggctcag tggtaagag cacagactgc tcttccaaag gtcccgagtt 10560
caaatcccac caatcacata gtggcttcca ttcccttta tggaaatgtct gaagactgct 10620
acagtgtact tacatataat aaataaaataa atcttaaaaa aaaaaaaccc agccgggcgt 10680
ggtggcgcac gcctttaatc ccagcaacttgg gggggcagag gcaggcggat tcctgagttc 10740
gacggccagcc tggctacag agtgagttcc acgacagccaa gaactacaca gagaacccct 10800
gtctcgaaaa aaaaaagaga gagagggaaag tgagagcgca ataatcttaa catttctgtg 10860
gttgtctttg ctgttagtcta ttctgataag caatgttggc ttgttcccaa ggttaggaagt 10920
aacatttctt tataaaaggt attgtctctg ctttattttt ctgttttattt tatggtgctg 10980
aggatggaaac ccaggaccct tggcaagccaa ggcttagtgc ttaccactga gccataactcc 11040
agccttgcac tgggggattt taggcaaggg ttcttaccact gagccacact ccccccaccc 11100
atccctctctt ggaagattctt aggcagtcc atacctagcc tttgatcttt taagacggtc 11160
ttactagagc tcagtt 11176

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/90 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 30715 A (ISACOFF EHUD Y ;SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFOR) 16 July 1998 (1998-07-16) page 29, line 5 -page 30, line 10; claims ---	1-8,10, 22-26, 32,34,35
X	WO 98 28971 A (LINK CHRISTOPHER ;UNIV TECHNOLOGY CORP (US)) 9 July 1998 (1998-07-09) page 22, line 3 - line 6; figure 1 page 26, line 24 - line 28; claims 11-19; figure 1; example 3 page 18, line 9 - line 13 ---	1,2,8, 10,12, 14-17
Y	--- -/-	1,2,7, 10-12, 14,17-20

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 June 2000

Date of mailing of the international search report

03/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CONTAG CH, ET AL.: "Visualizing gene expression in living mammals using a bioluminescent" PHOTOCHEMISTRY AND PHOTOBIOLOGY, (1997) VOL. 66, NO. 4, PP. 523-531. , XP000920570 the whole document ---	1,2,7, 10-12, 14,17-20
A	CONTAG PR, OLOMU IN, STEVENSON DK, CONTAG CH. : "Bioluminescent indicators in living mammals." NAT MED. , vol. 4, no. 2, February 1998 (1998-02), pages 245-247, XP000914588 the whole document ---	1
A	WO 98 36081 A (ANGELIS DINO A DE ;SLOAN KETTERING INST CANCER (US); MIESENBOCK GE) 20 August 1998 (1998-08-20) the whole document ---	1
A	WO 98 23633 A (CORNELL RES FOUNDATION INC) 4 June 1998 (1998-06-04) the whole document -----	1

Information on patent family members

PCT/US 99/30078

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9830715 A	16-07-1998	AU	5090498 A	03-08-1998
WO 9828971 A	09-07-1998	AU EP	5619298 A 0948612 A	31-07-1998 13-10-1999
WO 9836081 A	20-08-1998	EP	0981633 A	01-03-2000
WO 9823633 A	04-06-1998	AU	7410398 A	22-06-1998